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INTRODUCTION
There is an urgency to better identify patients with type 2 diabetes mellitus at early stages 
of chronic kidney disease (CKD) [1]. Approximately 387 million adults around the world 
are currently living with diabetes, and due to a relentless increase in the incidence of type 
2 diabetes, this estimate is projected to rise to 592 million by 2035 (Figure 1) [2]. Of those 
patients with type 2 diabetes, 20-40% will ultimately develop diabetic kidney disease 
(DKD). In addition, type 2 diabetes results in a high cardiovascular morbidity and mortality 
and a decrease in the patients’ health-related quality of life.
Figure 1. Number of people by region with diabetes in 2013 and projected number of cases in 2035. 
Adapted from the IDF Diabetes Atlas 2013 [2].
 
DKD, traditionally referred to as diabetic nephropathy, is based in part on the finding of 
elevated urinary albumin excretion (UAE), progressive decline in glomerular filtration rate 
(GFR), an increase in systemic blood pressure, and a high risk of kidney failure [3]. DKD is 
also associated metabolic disturbances. DKD is now the leading cause of end-stage renal 
disease (ESRD), and accounts for approximately 50% of dialysis and renal transplantation 
in developed countries [4]. There could be a sharp rise in the prevalence of ESRD over 
the next few decades [5], driven by population ageing and the increasing prevalence 
of diabetes (Figure 2). The costs for renal and cardiovascular related complications are 
extraordinarily high: costs for renal replacement therapies alone account for 3 to 5% of 
the total European Union (EU) health care budget and even more in other countries. The 
United States Renal Data System has reported that for patients aged 65 years and older 
with both CKD and diabetes, the total Medicare costs have increased more than 11 times 
in the past decade [6]. Additionally, in a group of patients with type 2 diabetes with early 
stage CKD in the United States, the 5-year healthcare costs were twice as high among 
those who progressed to a higher stage of CKD compared to who did not progress, and 
for patients with stage 3-4 CKD, the costs were more than threefold higher [7]. Thus, there 
is a strong economic and social imperative to improve the outcomes of type 2 diabetes. 
Early identification of patients with type 2 diabetes at risk of renal disease can lead to 
early intervention aimed at reducing the incidence of DKD and ultimately ESRD. There 
are many stakeholders that can benefit from early identification, number one being the 
patients themselves, their families, and society.
Figure 2. Estimated number of patients undergoing renal replacement therapy from 2010 to 
2030 worldwide (A) and by region (B). 95% CIs shown as error bars. Adapted from Liyanage et al. 
Lancet 2015 [5].
 
A biomarker is “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [8]. Estimated glomerular filtration rate (eGFR) and detection 
of albumin in urine (albuminuria) are the classical guideline-endorsed biomarkers for 
the classification of CKD [9]. These biomarkers are strong predictors of renal disease 
progression as well as cardiovascular disease and mortality. Reduction in eGFR and 
detection of microalbuminuria are considered the first clinical signs of renal disease. 
Reduced eGFR is the consequence of compromised kidney function and substantial loss 
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and destruction of the glomeruli, and the presence of microalbuminuria already indicates 
a permeable glomerular basement membrane. Both point to possibly irreversible damage 
to the kidney. However, renal damage at early disease stages rarely shows clinical 
characteristics. Therefore, on the everyday clinical level, early stage diagnosis and 
tailored treatment of DKD are still inadequate. In order to improve patient outcomes and 
reduce associated health-care costs, timely detection and prevention of progression of 
renal disease are needed.
Novel biomarker panels can improve identification of renal disease at its early stages. The 
search for novel biomarker panels to improve the early identification of patients at high-
risk for renal disease has been the priority of many researchers for many years. Novel 
biomarker panels can also have different roles for diagnosis, prognosis, and monitoring 
by improving risk stratification, help increase our understanding of renal disease 
pathophysiology, or provide insight into novel therapeutic targets.
Novel biomarker panels as predictors of renal disease
The past decade has produced a large number of papers published on novel biomarkers 
for renal disease. Many single proteins have been proposed as biomarkers of renal disease 
in type 2 diabetes and are measured by immunological assays [10-15]. Typically, these 
biomarkers capture one specific mechanism of disease such as inflammation, fibrosis, 
or tubular damage. These studies highlight the relevance of single disease mechanisms 
and provide important insight into the disease etiology. However, type 2 diabetes is a 
heterogeneous disease involving multiple pathophysiological mechanisms [16]. In theory, 
the measurement of several biomarkers simultaneously (a multi-marker approach) should 
improve risk stratification of patients at high risk for adverse events since it is unlikely that 
a single biomarker may possess useful diagnostic and prognostic power to fully capture 
the risk of renal disease in type 2 diabetes. Single biomarkers constantly face problems 
with individual, biological, and analytical variability.
To date, no one, single protein biomarker has been shown to significantly outperform 
albuminuria or eGFR as predictors of disease progression in longitudinal interventional 
studies. Alternatively, a panel of clearly defined biomarkers may provide a more robust 
and reproducible tool as a panel may tolerate changes in single biomarkers without 
jeopardizing their diagnostic precision and may offer a more realistic picture of disease 
and its underlying mechanisms. Multiple biomarker approaches are becoming more and 
more common in literature, though still not as prominent as single biomarker studies. 
There are however, few prospective studies of multiple biomarkers specifying type 2 
diabetes as the cause of renal disease. Some studies consider many biomarkers, but 
test each biomarker one by one, instead of a combined biomarker panel approach 
[10,11,15,17]. There are only a few studies in literature that focus on biomarker panels 
where two or more novel biomarkers are tested in combination to predict renal disease 
progression [18-21]. Measuring multiple biomarkers at once is becoming more and more 
realistic for clinical practice as advancing laboratory techniques with multiplex assays or 
mass-spectrometry technologies allow the simultaneous measurement of large number 
of biomarkers with minimal sample volume.
Multiple biomarker panels – Omics platforms
The measurement of multiple biological molecules has advanced significantly over the 
past years with the introduction of high-throughput omics screening platforms. An omics-
based test is defined as an assay composed of, or derived from, multiple molecular 
measurements and interpreted by a fully specified computational model to produce a 
clinically meaningful result. Such assays can measure a full spectrum of peptides or 
metabolites in a short amount of time [22]. The measurement of peptides and metabolites, 
known as proteomics and metabolomics, have emerged as strong tools in biomarker 
discovery [22,23].
Figure 3. The conceptual relationship of the genome, transcriptome, proteome, and metabolome. 
Adapted from Gerszten & Wang Nature 2008 [23].
Proteomics permit the rapid assessment of components of the proteome, which is the 
complete inventory of proteins (or peptides) present within a biological sample. Biological 
samples, such as urine, plasma, or serum, can be systematically analyzed with the goal 
of identifying, quantifying and discerning the function of all observable proteins [24]. In 
particular, urinary proteomics has gained much attention as a tool for the identification 
of diagnostic and prognostic biomarkers of renal diseases [25], and may represent an 
important step forward in the non-invasive diagnosis of renal diseases. Blood-derived 
proteomics studies are not as common as urine proteomics, a few reasons being that 
there is large heterogeneity and spread in abundance of proteins in blood and high 
exposure to proteolytic activity [26], which complicates the analysis of the blood proteome. 
Metabolomics, i.e. the measurement of low-weight intermediate metabolites (<500Da) and 
end-products of cellular functions in biological fluids has emerged as another potential 
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tool to discover novel biomarkers for renal disease. The metabolome can be viewed as 
the down-stream integration of biological information of the genome, transcriptome, 
proteome, and overall enzymatic reactions of an individual [23], and therefore enables 
the detection of short and long-term physiological or pathological changes occurring in 
chronic diseases. Omics-based approaches hold promise for new diagnostic tests, better 
understanding of pathogenesis, and evolution of a disease.
Novel biomarker panels for predicting response to therapy
Despite guideline recommended therapy for reduction of hypertension and albuminuria, 
not all patients with diabetes respond well to first line therapy intervening in the renin-
angiotensin-aldosterone system (RAAS) [27]. Furthermore, there is large intra- and inter-
individual variability in response to RAAS inhibiting therapy [28]. Many patients still have 
significant residual proteinuria [29]. In addition, a proportion of patients experience off-
target effects [30-32], which may contribute to progressive renal function loss. The reasons 
behind these individual differences in response to therapy are unknown, and may be 
related to differences in systemic vs. renal tissue-specific renin-angiotensin system activity 
[33], dietary sodium consumption [34], or difference in genetic make-up [35, 36], among 
other factors. One strategy to improve the current state-of-the-art treatment is to tailor 
drug therapy by using a complementary approach to attribute drug response variability 
to individual variability in underlying molecular mechanisms involved in the progression 
of disease. On one hand, the interplay of different processes such as inflammation, 
fibrosis, angiogenesis, or oxidative stress, appears to drive disease progression, but the 
individual contribution of each process varies. On the other hand, drugs address specific 
targets and thereby interfere in certain disease associated processes. At this level novel 
biomarker panels may help gain insight into which specific pathophysiological processes 
are involved in an individual followed by a rational assessment whether a specific drug’s 
mode of action indeed targets the relevant process. In this context, novel biomarker 
panels can be used to identify a group of patients more likely to beneficially respond 
to therapy. This may reduce this inter-individual variation in response to medication. 
However, studies evaluating whether novel biomarker panels can be used as predictors 
of response to therapy have only been marginally explored. 
Novel biomarker panels for monitoring drug effect
A third option for using novel biomarker panels are to use changes in biomarkers to 
monitor the effect of therapy. This is important because it allows one to make a better 
estimate of the drug effect after the individual is exposed to the drug for a short period 
of time. In addition, results of such studies may also provide insight into the mechanisms 
through which drugs exert renoprotective effects and yield novel biomarkers to monitor 
response to therapy in patients with type 2 diabetes and DKD. Studies evaluating whether 
changes in novel biomarker panels can be used as predictors of renal disease are limited 
in existing literature.
AIMS OF THIS THESIS
This thesis examines several different approaches of utilizing novel biomarker panels in 
diabetic kidney disease that can be used to predict disease progression, predict response 
to therapy, or monitor effects of therapeutic intervention.
Part 1. Novel biomarker panels for predicting disease progression
Part 1 begins by investigating the predictive ability of novel biomarker panels for the 
progression of renal disease in patients with type 2 diabetes. Chapter 2 evaluates 
the ability of a panel of novel, assay-based biomarkers representing different disease 
pathways to improve prediction of renal function decline in type 2 diabetes, and to 
assess their combined predictive performance of accelerated renal function decline. 
In Chapter 3, proteomic analysis is used to identify plasma peptides associated with 
transitioning in stage of albuminuria in hypertension or type 2 diabetes, and examines 
whether two classifiers, one for hypertension and another for type 2 diabetes, are able to 
predict the transition of stage of albuminuria. In Chapter 4, metabolomics is performed 
to investigate the predictive ability of urine and plasma metabolites for the progression of 
renal dysfunction in patients with type 2 diabetes, and tests whether the metabolites are 
specific to type 2 diabetes by assessing the metabolites in individuals with hypertension 
without type 2 diabetes.
Part 2. Novel biomarker panels for predicting response to therapy and monitoring 
drug effect
Part 2 examines novel biomarker panels for predicting response to therapy in diabetes 
mellitus and monitoring the effect of therapeutic intervention. Chapter 5 first discovers 
and then validates a serum metabolite classifier that predicts response in albuminuria to 
angiotensin receptor blocker (ARB) therapy in patients with diabetes mellitus. Chapter 
5 further integrates the identified metabolites in a molecular process model capturing 
disease pathophysiology at the interface of drug mechanism of action to decipher 
the underlying molecular processes driving albuminuria response to ARB. Chapter 6 
assesses the correlation between a previously discovered metabolomics signature of 
diabetic kidney disease and eGFR in patients with type 2 diabetes and nephropathy, and 
evaluates the effect of atrasentan on these urinary metabolites.
This thesis ends by discussing future perspectives for using novel biomarker panels to 
improve on the status quo of choosing drugs for treatment of DKD in patients with type 2 
diabetes and as a strategy to guide personalized medicine.
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ABSTRACT
Objectives: We aimed to identify a novel panel of biomarkers predicting renal function 
decline in type 2 diabetes, using biomarkers representing different disease pathways 
speculated to contribute to the progression of diabetic nephropathy.
Methods: A systematic data integration approach was used to select biomarkers 
representing different disease pathways. Twenty-eight biomarkers were measured in 
82 patients seen at an outpatient diabetes center in the Netherlands. Median follow-up 
was 4.0 years. We compared the cross-validated explained variation (R2) of two models 
to predict eGFR decline, one including only established risk markers, the other adding 
a novel panel of biomarkers. Least absolute shrinkage and selection operator (LASSO) 
was used for model estimation. The C-index was calculated to assess improvement in 
prediction of accelerated eGFR decline defined as ≤-3.0 mL/min/1.73m2/year.
Results: Patients’ average age was 63.5 years and baseline eGFR was 77.9 mL/
min/1.73m2. The average rate of eGFR decline was -2.0 ± 4.7 mL/min/1.73m2/year. 
When modeled on top of established risk markers, the biomarker panel including matrix 
metallopeptidases, tyrosine kinase, podocin, CTGF, TNF-receptor-1, sclerostin, CCL2, 
YKL-40, and NT-proCNP improved the explained variability of eGFR decline (R2 increase 
from 37.7% to 54.6%; p=0.018) and improved prediction of accelerated eGFR decline 
(C-index increase from 0.835 to 0.896; p=0.008).
Conclusions: A novel panel of biomarkers representing different pathways of renal 
disease progression including inflammation, fibrosis, angiogenesis, and endothelial 
function improved prediction of eGFR decline on top of established risk markers in type 2 
diabetes. These results need to be confirmed in a large prospective cohort.
INTRODUCTION
The growing prevalence of type 2 diabetes is a great global health problem. Type 2 
diabetes is the leading cause of chronic kidney disease (CKD) in the United States and is 
associated with high cardiovascular risk [1, 2]. Optimizing treatment has been shown to 
improve life expectancy, reduce costs, and lower the risk of death in patients with type 2 
diabetes [3, 4]. Despite important progress in improving therapy, many patients are still 
at risk for renal disease.
Early identification of patients with type 2 diabetes at risk for progressive renal function 
loss during the early stages of disease may lead to better patient outcomes. In clinical 
practice, estimated glomerular filtration rate (eGFR) and albuminuria are used to assess 
renal function when gold-standard measured GFR is not feasible or practical. The search 
for novel biomarkers that improve risk prediction models on top of established risk 
markers has been a priority of many researchers for many years. Various studies have 
assessed the performance of single biomarkers representing a single, disease-associated 
pathway to predict progression of renal function loss in type 2 diabetes [5, 6]. However, 
because type 2 diabetes is a multifactorial disease, several pathways involving pro-
inflammatory, pro-fibrotic, and angiogenic processes, among others, are activated during 
the course of the disease [7]. Given the complexity of the multiple pathophysiological 
processes involved in progression of type 2 diabetes together with the intra-individual 
variability of biomarkers, it is questionable if a single biomarker may possess useful 
diagnostic and prognostic power. Alternatively, a combination of biomarkers that capture 
different pathways of renal damage may provide a more realistic picture of a patient’s 
actual pathophysiological status and hence may yield better assessment of disease 
prognosis performance. 
Therefore, we aimed to identify a novel panel of biomarkers representing different disease 
pathways that are speculated to contribute to the progression of renal disease in type 2 
diabetes, and to evaluate their combined predictive performance of accelerated renal 
function decline.
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This observational cohort study was performed in Caucasian patients from Zwolle, 
the Netherlands, who participated in the PREvention of DIabetic ComplicaTIONS 
(PREDICTIONS) study [8]. Patients aged 35-75 with type 2 diabetes with a documented 
duration of ≥5 years were eligible for the PREDICTIONS study. Type 2 diabetes was defined 
according to World Health Organization criteria [9]. A total of 82 patients were recruited in 
2007 - 2008 and followed for a median of 4.0 [1st, 3rd quartile 3.7 to 4.4] years. Follow-up 
information on urinary albumin:creatinine ratio (UACR), serum creatinine, cholesterol, and 
glycated hemoglobin (HbA1c) was obtained from electronic patient files from visits to the 
outpatient diabetes clinic during their annual visit to the diabetes specialist. 
Ethics Statement
The PREDICTIONS study was approved by the ethical review boards of the medical 
ethics committees of the Isala Clinics in Zwolle and of the University Medical Center in 
Groningen, the Netherlands, and was conducted in accordance with the guidelines of the 
Declaration of Helsinki. All patients gave written, informed consent.
Selection of biomarkers, sample collection, preparation, and measurement
Twenty-eight biomarkers were selected for testing using three distinct approaches, namely 
a literature review [10], identification of molecular processes and pathways [7], and ranking 
of consolidated Omics signatures [11]. A complete list of biomarkers is presented in Table 
1, and the biomarker selection procedure is described in Supplemental Appendix 1.
Fasting serum and plasma samples were stored at -80°C. All samples were stored for 
4 - 5 years and did not undergo any freeze-thaw cycles. Biomarkers were assayed on 
baseline samples by enzyme-linked immunosorbent assay (ELISA) or multiplex assay by 
Biomarker Design Forschungs GmbH (BDF), in Vienna, Austria, except for connective 
tissue growth factor (CTGF). CTGF was measured using specific antibodies (FibroGen Inc., 
San Francisco, USA) directed against distinct epitopes in the amino-terminal fragment of 
CTGF, as described previously [12]. All assays were used according to manufacturer’s 
instructions. A complete list of assays, and information on stability and determination of 
limits of detection are available in Supplemental Appendix 2. All biomarker analyses were 
performed blinded, and the results were then reported back to the study center for analysis.
Statistical analysis
Analyses were performed with SAS software (version 9.2; SAS Institute, Cary, NC) and 
R version 3.0.2 [13] using the packages mice and glmnet [14, 15]. Data are presented 
as mean (standard deviation) or median [1st, 3rd quartile] for skewed variables. Graphical 
techniques were used to detect outliers. The natural logarithm of UACR and the binary 
logarithm of all biomarkers were used to normalize their distributions. Log transformed 
variables were used in all regression analysis. Values below the detection limit were set 
to the detection limit. Variables with missing values were multiply imputed using chained 
equations [16]. Five of the twenty-eight biomarkers had values with >10% missing or 
>25% below the detection limit were not used in analysis. Details on our implementation 
of multiple imputation can be found in Supplemental Appendix 3. All p-values were two-
tailed, and values <0.05 were considered statistically significant.
The outcome of interest was eGFR decline, defined as the within-patient annual eGFR 
slope. EGFR decline was calculated using a minimum of 3 serum creatinine measurements 
during follow-up by fitting a straight line through the eGFR values using linear regression. 
The eGFR value at each time-point was estimated using the 4-variable Modification of 
Diet in Renal Disease (MDRD) Study Equation [17]. 
Statistical modeling consisted of several steps. First, established risk markers were 
selected as best predictors of eGFR decline using least absolute shrinkage and selection 
operator (LASSO) selection [18]. The LASSO is advantageous for small samples sizes 
because it places restrictions on the absolute sizes of the regression coefficients in the 
model while optimally selecting the subset of variables that best predicts the outcome. 
This restriction also controls for multicollinearity. LASSO involves the estimation of 
a tuning parameter controlling the amount of restriction, which was optimized by 
minimizing the leave-one-out cross-validated mean squared error (MSE) of prediction. 
The established risk markers listed in Table 2 were considered as potential predictors of 
eGFR decline. First, all established risk markers were included in a multivariable model 
using LASSO regression. The best predictors of eGFR decline were then identified from 
the multivariable model and are reported in the results section. Second, univariate linear 
models were fit for each of the novel biomarkers to assess a single biomarker association 
with eGFR decline. Third, multivariable models were then fit by linear regression with 
single novel biomarkers adjusting for the selected established risk markers. Fourth, a 
multivariable model including the selected established risk markers and all biomarkers 
was fit using the LASSO selection in order to find the best subset of predictors. 
Bootstrap validation was performed to determine the validity of the model to assess the 
ability of the biomarker panel to predict renal function decline. The bootstrap (N=1000) 
was used to evaluate selection probabilities of each biomarker, and to construct 95% 
confidence intervals and two-sided p-values for the regression coefficients by the 
percentile method. A global p-value testing the global null hypothesis of no added value 
of the biomarkers was constructed by counting the number of bootstrap resamples in 
which the multivariable biomarker model led to a smaller cross-validated MSE than a 
model based on the established risk markers alone. In a simple bootstrap validation, 
LASSO models were fit to the 1000 bootstrap resamples, each time optimizing the cross-
validated MSE as described above. These models were then applied to the original data 
without modification. The resulting MSE was calculated by averaging the squared average 
difference between the original outcome and the predicted outcome for each patient. 
This was done for models only considering the established risk markers, and for models 
considering clinical and biomarker predictors. From the MSEs, R2 measures were finally 
derived in order to determine whether the biomarkers significantly improved prediction.
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Table 2. Baseline characteristics in patients with type 2 diabetes (n=82).
Risk marker Baseline values
Age (years) 63.5 ± 9.4
Male Gender (%) 44 (53.7)
Current smoker (%) 8 (9.6)
Body mass index (kg/m2) 32.4 ± 6.3
Systolic blood pressure (mmHg) 135.2 ± 16.3
Diastolic blood pressure (mmHg) 72.7 ± 10.5
Duration of diabetes (years) 15.7 ± 7.3
Baseline laboratory measurements
  UACR (mg/mmol) 1.2 [0.5, 57.7]
  Serum creatinine (µmol/L) 88.4 ± 33.5
  eGFR (mL/min/1.73m2) 77.9 ± 22.6
  HDL Cholesterol (mmol/L) 1.3 ± 0.4
  LDL Cholesterol(mmol/L) 2.0 ± 0.6
  HbA1c (%) 7.7 ± 1.3
Medication use
  RAAS* (%) 27 (42.9)
  Insulin* (%) 58 (92.1)
  Oral diabetic medication* (%) 35 (55.6)
Data are reported as mean ± standard deviation or number (percent) or median [1st, 3rd quartile].
*Data available for n = 63. 
The added value of the biomarker panel was also evaluated using the discriminative 
index (C-index) by dichotomizing the observed outcome variables into accelerated or 
non-accelerated renal function decline (eGFR decline ≤-3 or >-3 mL/min/1.73m2/year, 
respectively) and comparing this with predicted probabilities of eGFR decline (see 
Supplemental Appendix 3). The C-index was also calculated using the simple bootstrap 
validation scheme, and the differences in the C-index between a model of only established 
risk markers and a model of established risk markers plus biomarkers were assessed. 
The threshold of -3 mL/min/1.73m2 was based on prior studies and its concurrence with 
the high quartile of eGFR decline [19, 20]. 
RESULTS
Baseline characteristics and association with eGFR decline
Baseline characteristics are presented in Table 2. The average age of the cohort was 63.5 
(SD 9.4) years and 53.7% were male. Type 2 diabetes was well established in the study 
population with average diabetes duration of 15.7 (SD 7.3) years. Renal function was 
relatively preserved in the cohort with an average eGFR of 77.9 (SD 22.6) mL/min/1.73m2 
at baseline. Median UACR was 10.6 [1st, 3rd quartile: 4.42, 510.1] mg/g. The average rate 
of eGFR decline over the median of 4.0 [1st, 3rd quartile: 3.7, 4.4] years of follow-up was 
-2.1 (SD 4.5) mL/min/1.73m2/year. 
The following best predictors of eGFR decline were selected from the LASSO selection: 
baseline UACR, current vs. never smoker, sex, systolic and diastolic blood pressure, use 
of oral diabetic medication, and baseline eGFR (Supplemental Figure 1).
Biomarker concentrations and associations with eGFR decline
Baseline biomarker concentrations and univariate associations of the single biomarkers 
with eGFR decline are reported in Table 1. Higher concentrations of the individual 
biomarkers matrix metallopeptidases 2 (MMP2) (p = 0.04), matrix metallopeptidases 7 
(MMP7) (p < 0.01), chitinase 3-like 1 (YKL-40) (p = 0.01), tumor necrosis factor receptor-1 
(TNFR1) (p < 0.01), podocin (NPHS2) (p = 0.01), and endostatin (frag.COL18A1) (p = 0.03) 
were significantly associated with eGFR decline. When single biomarkers were modeled 
adjusting for established risk markers, MMP7, tyrosine kinase (TEK), and TNFR1 were 
independently associated with eGFR decline (Table 1). For every two-fold increase in 
the log concentration of MMP7, TEK, or TNFR1, a corresponding decrease of eGFR of 
0.77 (p = 0.04), 0.90 (p = 0.02), and -2.1 (p = 0.03) mL/min/1.73m2/year, respectively, 
was observed. 
When these three biomarkers were modeled on top of the established risk markers, 
they did not improve the explained variability (R2) of eGFR decline (35.7% compared to 
37.7% of the reference model; p = 0.988). The three biomarkers also did not increase the 
C-index for prediction of accelerated renal function decline (0.860 compared to 0.835 of 
the reference model; p = 0.262).
Selection of optimal combination of established risk markers and biomarkers
Although most individual biomarkers were not found to be independently associated with 
eGFR decline, we hypothesized that the combination of biomarkers representing different 
disease pathways may improve prediction of eGFR decline. In a multivariable LASSO 
selection, the optimal model for prediction of eGFR decline was achieved after inclusion of 
19 variables (Figure 1). The model included a subset of 13 novel biomarkers representing 
fibrosis, angiogenesis, inflammation, mineral metabolism, and endothelial function that, 
when added to the established risk markers, more accurately predicted the rate of eGFR 
decline (Table 3). The explained variability of the model (R2) markedly increased from 
37.7% to 54.6% (p = 0.018) and predicted a higher probability of accelerated renal 
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function decline (Figure 2). There was also a significant improvement in the C-index of 
the optimal model for prediction of accelerated renal function decline (0.896 compared to 
0.835 of the reference model; p = 0.008) (Figure 3). 
To investigate the importance of each of the predictors in the optimal model, we omitted, 
one by one, variables from the full model. If a variable was omitted from the model, 
the other predictor variables could be selected instead. Only the omission of UACR 
or systolic blood pressure resulted in relevant inclusions of other novel biomarkers 
(Supplemental Table 1).
Table 3. Optimal model of established risk markers and biomarkers, results from LASSO selection 
and bootstrap resampling (N=1000). 
Variable mean β 95% CI* p
Selection 
probability†
Baseline UACR -0.509 -0.834, -0.159 0.002 0.999
Systolic blood pressure 0.049 0.010, 0.085 0.012 0.994
MMP2 7.382 0.010, 0.085 0.018 0.993
TEK -0.793 -1.416, -0.139 0.018 0.993
Baseline eGFR -0.072 -0.130, -0.014 0.026 0.987
CTGF -5.911 -10.358, -0.913 0.026 0.987
MMP7 -0.540 -1.191, 0.0 0.078 0.966
Current vs. never smoker -1.593 -3.905, 0.0 0.144 0.943
MMP8 0.472 0.0, 1.036 0.134 0.935
NPHS2 -1.509 -3.667, 0.0 0.206 0.908
MMP1 0.392 -0.081, 1.051 0.298 0.897
TNFR1 -1.618 -4.037, 0.0 0.228 0.889
SOST 0.983 -0.014, 2.556 0.278 0.888
Oral diabetic medication -1.060 -2.673, 0.0 0.274 0.884
MMP13 -0.363 -1.835, 1.020 0.798 0.820
Sex 0.792 -0.905, 2.814 0.592 0.785
CCL2 0.461 -1.228, 2.672 0.854 0.781
YKL-40 -0.405 -1.358, 0.019 0.518 0.771
NT-proCNP 0.756 -0.002, 2.452 0.568 0.742
*95% confidence interval, estimated from the 2.5th and 97.5th percentiles of the bootstrap distribution. 
†The relative frequency of the marker being included in the model across 1000 bootstrap resamples.
Figure 1. LASSO selection of optimal model of established risk markers and biomarkers: cross 
validated mean squared error (Y-axis; black bullets; MSE) vs. amount of restriction (X-axis; 
log(Lambda)). Vertical bars refer to standard errors across the 82 cross-validations. The best cross-
validated MSE was obtained after inclusion of 19 variables (step 31), which included baseline UACR, 
MMP7, current vs. never smoker, sex, TEK, MMP2, systolic blood pressure, baseline eGFR, TNFR1, 
NPHS2, CTGF, use of oral diabetic medication, YKL-40, MMP1, MMP13, MMP8, SOST, CCL2, and 
NT-proCNP.
Figure 2. Predicted probability of accelerated renal function decline (eGFR decline ≤-3 or >-3 mL/
min/1.73m2/year) in patients with type 2 diabetes.
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Figure 3. C-index for prediction of accelerated renal function decline (eGFR decline <-3 or >-3 mL/
min/1.73m2/year) for a) established risk markers (reference model: baseline UACR, current vs. never 
smoker, sex, systolic and diastolic blood pressure, use of oral diabetic medication, and baseline 
eGFR) (C-index = 0.835), b) 3-biomarker model (MMP7, TEK, and TNFR1 on top of reference model) 
(C-index = 0.835; p = 0.262 compared to reference model), and c) Optimal model (baseline UACR, 
MMP7, current vs. never smoker, sex, TEK, MMP2, systolic blood pressure, baseline eGFR, TNFR1, 
NPHS2, CTGF, use of oral diabetic medication, YKL-40, MMP1, MMP13, MMP8, SOST, CCL2, and 
NT-proCNP) (C-index = 0.896; p = 0.008 compared to reference model). 
DISCUSSION
In this study, we established that a combination of different biomarkers representing 
different pathways that are speculated to be involved in the progression of renal disease 
improves prediction of eGFR decline. Although some biomarkers were not independently 
associated with eGFR decline, when combined into a multi-biomarker model, the 
combination of biomarkers improved renal risk stratification, suggesting that these 
biomarkers may possess synergistic effects in predicting renal function loss. 
Diabetic kidney disease is characterized by the functional impairment and structural 
remodeling of the kidney and is linked to the changes in the kidney. Diabetic nephropathy 
is well characterized by glomerular hypertrophy and hyperfiltration, inflammation of 
glomeruli and tubuliointerstitial regions, and reduction of cell number by apoptosis and 
accumulation of extracellular matrix (ECM). Each of the biomarkers selected in the optimal 
model has been associated with one of these pathophysiological processes involved in 
diabetic nephropathy. 
First, chronic inflammation has long been identified in the pathogenesis of type 2 
diabetes and progression of diabetic nephropathy, and inflammation is well represented 
by the biomarkers included in the optimal model. Tumor necrosis factor alpha is a 
key mediator of inflammation and plays a role in apoptosis. It mediates its signal via 
two distinct receptors, TNFR1 and TNFR2. Circulating forms of both TNF receptors 
were recently shown to predict end-stage renal disease (ESRD) in type 2 diabetes [6]. 
Monocyte chemoattractant protein-1 (CCL2), another marker of inflammation, is a potent 
C-C chemokine for monocyte/macrophages and T cells. Increased amounts of CCL2 
have been detected in renal biopsies and urine from patients with diabetic nephropathy 
[21], and CCL2 has been shown to be a marker of late stage diabetic nephropathy 
[22]. Currently there are a couple of clinical trials ongoing that target CCL2 receptor as 
a means to delay progression of diabetic nephropathy (www.clinicaltrials.gov identifier 
NCT01712061, NCT01752985). Results of these studies will provide more insight whether 
CCL2 is a causal factor or consequence of renal function loss. Additionally, YKL-40, a 
proinflammatory marker, has been identified as an independent factor associated with 
albuminuria in early stage nephropathy in type 2 diabetes and might have a useful role as 
a noninvasive marker for the early diabetic nephropathy detection [5, 23]. High YKL-40 
levels have been shown to predict mortality in patients with type 2 diabetes [24]. Future 
mechanistic studies exploring the interplay between different inflammatory markers will 
help determine which markers are causal factors or consequences in the progression of 
diabetic kidney disease.
Second, the optimal model included several biomarkers linked to pro-fibrotic processes. 
Fibrosis, resulting from expansion and change in composition of ECM in the kidney, 
is a well-known pathologic feature of diabetic complications. Altered expression of 
matrix metalloproteinases (MMPs) have been implicated in the progression of diabetic 
nephropathy by affecting the breakdown and turnover of ECM. In mice, the overexpression 
of MMP-9 has been shown to induce podocyte dedifferentiation, interrupt podocyte cell 
integrity, and promote podocyte monolayer permeability to albumin and extracellular 
matrix protein synthesis [25]. In humans, serum MMP7 has been shown to be increased 
in diabetic renal disease and diabetic diastolic dysfunction [26]. In support of this, our 
study showed that higher concentrations of MMP7 were independently associated with 
eGFR decline. CTGF is another well investigated pro-fibrotic biomarker that was included 
in the optimal model. CTGF, which is upregulated in diabetic nephropathy and contributes 
to extracellular matrix accumulation, has been associated with both early and late stage 
diabetic nephropathy [12, 22]. Down-regulation of CTGF and vascular endothelial growth 
factor-A (VEGF-A) in diabetic nephropathy is speculated to be a result of podocyte loss 
[27]. Our data, in conjunction with data from literature, support the importance of fibrotic 
pathways in the initiation and progression of diabetic kidney disease.
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Third, we included a marker representing angiogenesis. Angiogenesis is the formation of 
new blood vessels from pre-existing vasculature. Neovascularization has been implicated 
in the genesis of diverse diabetic complications such as retinopathy, impaired wound 
healing, neuropathy, and diabetic nephropathy. In both physiological and pathological 
angiogenesis, tyrosine kinase  (TEK) plays a key role. TEK is principally expressed in 
endothelial cells and inhibits vascular permeability and tightens preexisting vessels [28]. 
Additionally, TEK plays a critical role in the angiogenesis of endothelial cells via binding 
to angiopoietin [29]. 
Finally the model included a marker representing endothelial function. Endothelial 
dysfunction is considered an initial step of the atherosclerotic process because diabetes 
substantially impairs vasodilating properties of the endothelium which leads to impaired 
vasodilation and ultimately endothelial dysfunction [30]. C-type natriuretic peptide 
(CNP), a member of the natriuretic peptide family, is produced in vascular endothelium. 
Our study implies that natriuretic (NT)-proCNP, the N-terminal fragment of the C-type 
natriuretic peptide precursor, contributes to prediction of eGFR decline. NT-proCNP has 
been shown to be associated with arterial stiffness, endothelial dysfunction, and early 
atherosclerosis [31], however the link of NT-proCNP to type 2 diabetes and nephropathy 
is still under investigation. 
In our study, most biomarkers were not able to individually predict eGFR decline 
after adjustment for established risk markers, and the model of 3 biomarkers did not 
statistically improve prediction. Rather, the optimal model of 13 biomarkers yielded best 
and significant improvements in the C-index. Advancing laboratory techniques allowing 
simultaneous measurement of many biomarkers are becoming more and more realistic 
in clinical practice. Whether the biomarkers identified are either involved in the causal 
pathway contributing to CKD progression, or are markers of its risk, or are merely the 
end-product of existing pathological processes, remains an important and unresolved 
question that requires further exploration. A future study on etiology to examine the 
causal relationship between these biomarkers as risk factors of renal disease would be 
appropriate, and issues of confounding could then be addressed. Testing for confounding 
was beyond the scope of this prediction study; however, we were able to investigate 
the importance of each of the predictors in the optimal model. Baseline UACR was 
found to have the largest impact on eGFR decline, and only the omission of baseline 
UACR or systolic blood pressure allowed inclusions of other novel biomarkers into the 
model. The combination of multiple biomarkers in the final, optimal model appears to be 
more accurate in risk stratification for accelerated renal function decline in patients with 
type 2 diabetes.
There are some studies in literature that use a multi-biomarker approach for risk prediction 
in CKD. A recent study showed that the combination of a panel of biomarkers including 
inflammation, fibrosis, and cardiac stretch and injury improved prediction of death in a 
Canadian CKD cohort; however, this study was conducted in a cohort with different CKD 
etiology [32]. Additionally, in another study of multiple protein biomarkers, 17 urinary 
and 7 plasma biomarkers were evaluated to predict progression. C-terminal FGF-23 and 
VEGF-A were found to be associated with the end point independent of urine albumin/
creatinine. In that study many biomarkers were tested one by one, but did not use a 
combined biomarker approach to predict renal disease progression [33]. Furthermore, 
a panel of multiple urinary cytokines was found to predict rapid renal function decline 
in overt diabetic nephropathy [34]. However, that study included a heterogeneous 
population of patients with both type 1 and type 2 diabetes. Finally, in a post-hoc study 
from the IRMA-2 trial showed that multiple biomarkers of endothelial dysfunction and 
possibly inflammation were predictors of progression to diabetic nephropathy in patients 
with type 2 diabetes and microalbuminuria independent of traditional risk markers [35]. 
Advances in high throughput analytical methods has fueled novel biomarker discovery. 
Two such platforms, namely proteomics and metabolomics, have shown promise in 
multi-biomarker discovery for the diabetic CKD. A urinary peptide classifier, consisting 
of 273 defined urinary peptides, was recently discovered as a good classifier in patients 
with CKD [36] and validated in an independent cohort as a predictor of albuminuria 
progression in patients with type 2 diabetes [37]. Furthermore, a panel of 13 metabolites 
linked with mitochondrial metabolism was significantly reduced in CKD patients with 
diabetes compared to healthy controls [38], and the combination of plasma metabolites 
butenoylcarnitine and histidine, and urine metabolites glutamine, tyrosine, and hexoses 
were able to predict the progression from micro- to macroalbuminuria in patients with 
type 2 diabetes [39].
Interestingly in our study, HbA1c and duration of diabetes were not strong predictors 
of eGFR decline, whereas albuminuria was identified as the strongest predictor. The 
exclusion of HbA1c and duration of diabetes from the reference model may be due to 
small variations in these parameters within this population. Regarding albuminuria, there 
is evidence that demonstrates albuminuria as a strong risk predictor of renal function loss 
in patients with type 2 diabetes [40-43]. Moreover, experimental data show that increased 
albumin exposure to the tubuli causes tubulo-interstitial damage through activation of 
pro-inflammatory mediators, which leads to a progressive decline in glomerular and 
tubular function, ultimately culminating in end-stage renal disease [44, 45]. Our data on 
albuminuria as a strong predictor of eGFR decline are in line with this and highlight the 
importance of screening for high albuminuria to identify individuals at risk of progressive 
renal function loss. At the same time, it may be interesting to explore the predictive 
ability of urine biomarkers alongside albuminuria for renal disease progression as urine 
is considered quite a suitable substrate to measure biomarkers linked to kidney disease 
due to the practical advantages of collecting urine compared to blood samples. Since our 
study measured biomarkers in blood, we are unable to speculate if urine biomarkers, or the 
combination of both blood and urine markers, would yield similar predictive capabilities.
There are strengths and limitations to this study. A clear strength is the use of a multi-
marker, multi-pathway approach for identifying and testing biomarkers in a population of 
patients with type 2 diabetes over approximately 4 years of follow-up. The clear limitation 
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is the measurement of multiple biomarkers in a small sample size. However, as advancing 
laboratory techniques generate larger amounts of data, methods of data analysis to 
accommodate “big data” with smaller sample sizes are needed. The rigorous statistical 
method of the LASSO regression allowed for modeling many biomarkers in the small 
sample size, and multiple imputation was used to avoid truncating observations due to 
missing data. The true predictive capacity of the model could have been overestimated 
due to the prediction model being developed and tested in the same sample, and we 
do agree that external validation is necessary. In the absence of external validation, we 
performed internal bootstrap validation in an attempt to minimize this limitation [46]. GFR 
was estimated using a serum creatinine-based equation instead of by direct measurement, 
which may have contributed to misclassification bias. However, this could have only 
resulted in an underestimation of the strength of the reported associations. We chose to 
omit five biomarkers from our analysis due to many missing or below limit of detection 
values. While the exclusion of these biomarkers from our analysis may have resulted 
in an underrepresentation of pathways, the omission of biomarkers could have only 
underestimated the predictive ability of the biomarker panel. Additional limitations include 
the lack of information concerning insulin use, diet, and renin-angiotensin-aldosterone 
system medication type and dose, which clearly represent unmeasured confounders 
in our study.
In conclusion, novel biomarkers may provide deeper understanding into the pathophysiology 
of CKD or diabetic nephropathy but identification of progression-associated molecular 
pathways via biomarkers as proxy may also help to identify novel therapeutic targets. We 
identified a novel panel of biomarkers representing different pathways of renal damage, 
including inflammation, fibrosis, angiogenesis, and endothelial function. This combined 
panel improved prediction of accelerated renal function decline in patients with type 2 
diabetes on top of established risk markers. The results of this study need to be validated 
in a large, prospective cohort to validate and assess its applicability in a broad type 2 
diabetes population. 
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SUPPLEMENTAL APPENDIX 1. SELECTION OF BIOMARKERS
Biomarker candidates were selected following three strategies in the realm of integrative 
evaluation, namely a manual consolidation effort and two algorithmic approaches. 
Common denominator of the procedures was evaluation of a candidate’s relevance 
in the context of molecular processes and pathways of putative relevance in diabetic 
nephropathy. Respective molecular pathways were extracted from the title and abstracts 
of publications retrieved with the following NCBI PubMed query: (“diabetic nephropathy”[ti] 
OR “diabetic nephropathies”[ti]) AND (pathway[ti] OR pathways[ti]).
Manual consolidation of biomarker candidates started with a literature review resting 
on PubMed MeSH annotation “biological markers” [mh] and “Diabetic Nephropathies” 
[mh]. Utilizing mechanistic context literature reviewing based on NCBI GeneRIF (ftp://ftp.
ncbi.nih.gov/gene/GeneRIF/) and tissue specific expression information retrieved from a 
gene expression dataset on 32 human tissues (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE7905) as well as from abundance information available in GeneCards 
(http://www.genecards.org) twelve biomarker candidates were selected for experimental 
evaluation utilizing ELISA-based assays: zinc-binding alpha-2-glycoprotein 1 (AZGP1); 
endostatin (fragment of COL18A1); connective tissue growth factor (CTGF); fibroblast 
growth factor 23 (FGF23); galectin-3 (LGALS3); monocyte chemoattractant protein-1 
(CCL2); nephrin (NPHS1); podocin (NPHS2); neuropilin-1 (NRP1); amino terminal pro 
C-type natriuretic peptide (NT-proCNP); sclerostin (SOST), and tumor necrosis factor 
receptor 2 (TNFR2).
The second biomarker selection procedure utilized a molecular model representation 
of diabetic nephropathy [1]. In brief, the methodology consolidates Omics signatures 
associated with diabetic nephropathy on a molecular interaction network, and segments 
the induced subgraph into molecular units utilizing topological criteria. Based on this 
approach the following biomarker candidates were selected for multiplexed (Luminex-
based) analysis: chitinase 3-like 1 (YKL-40); chemokine (C-X-C motif) 1 (CXCL1); 
chemokine (C-X-C motif) 10 (CXCL10); epidermal growth factor (EGF); growth hormone 
1 (GH1); hepatocyte growth factor (HGF); interleukin 1 beta (IL1B); leptin (LEP); a set of 
matrix metallopeptidases (MMP13, MMP2, MMP7, MMP8); tyrosine kinase (TEK); tumor 
necrosis factor receptor superfamily, member 1A (TNFR1), and vascular endothelial 
growth factor A (VEGF-A). This selection procedure also included CCL2 already being 
derived as candidate from manual consolidation.
The third biomarker selection procedure rested on a ranking procedure of consolidated 
Omics signatures utilizing annotation from Genecards [2]. Next to the candidates CXCL1, 
CXCL10, EGF, IL1B and MMP2 also selected based on the molecular model analysis, 
CCL2 selected on the basis of the molecular model as well as on the basis of manual 
consolidation, and endostatin also selected based on manual evaluation, Interleukin 
1 alpha (IL1A) and matrix metallopeptidases 1 (MMP1) were included as additional 
candidates for experimental evaluation.
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SUPPLEMENTAL APPENDIX 2. BIOMARKER ASSAY INFORMATION
At the time of the study, most assays were available directly from the manufacturer, 
except for FGF23 and Endostatin (Biomedica/Biomarker Design Forschungs GmbH 
(BDF), Vienna, Austria) which were under development and validation  according to the 
International Conference of Harmonization (ICH). Both assays met all ICH standards.
Regarding the limit of detection, for Biomedica/BDF assays, the Lower Limit of Detection 
(LLD) was defined as the calculated concentration of the lowest standard point plus three 
times the standard deviation. For Fibrogen (FibroGen Inc., San Francisco, USA), the 
detection limit of the CTGF assay was 4 pmol/l, and intra- and interassay variations were 
6 and 20%, respectively. For R&D Systems (R&D Systems, Minneapolis, USA) assays, 
the Minimum Discriminatory Difference (MDD) was determined by adding two standard 
deviations to the mean optical density value of twenty zero standard replicates and 
calculating the corresponding concentration. For USCN (USCN Life Science Inc., Wuhan, 
Hubei, China) assays, the LLD was defined as the lowest protein concentration that 
could be differentiated from zero. It was determined by adding two standard deviations 
to the mean optical density value of twenty zero standard replicates and calculating the 
corresponding concentration.
Regarding stability of the biomarkers, we have no information about long term stability. 
USCN recommends to avoid repeated freeze/thaw cycles. R&D Systems and Biomedica/
BDF have tested the freeze/thaw stability and state that the analytes are stable for at least 
3 freeze/thaw cycles.
Biomarker Assay Manufacturer
Endostatin (Frag.COL18A1) ELISA Biomedica/BDF
Amino terminal pro C-type natriuretic peptide (NT-proCNP) ELISA Biomedica/BDF
Fibroblast growth factor 23 (FGF23) ELISA Biomedica/BDF
Sclerostin (SOST) ELISA Biomedica/BDF
Connective tissue growth factor (CTGF) ELISA Fibrogen
Podocin (NPHS2) ELISA USCN
Zinc-binding alpha-2-glycoprotein 1 (AZGP1) ELISA USCN
Nephrin (NPHS1) ELISA USCN
Neuropilin-1 (NRP1) ELISA USCN
Tumor necrosis factor receptor-2 (TNFR2) ELISA R&D Systems
Monocyte chemoattractant protein-1 (CCL2) Multiplex R&D Systems
Tumor necrosis factor receptor-1 (TNFR1) Multiplex R&D Systems
Chitinase 3-like 1 (YKL-40) (ng/mL) Multiplex R&D Systems
Chemokine (C-X-C motif) 1 (CXCL1) Multiplex R&D Systems
Chemokine (C-X-C motif) 10 (CXCL10) Multiplex R&D Systems
Matrix metallopeptidase 1 (MMP1) Multiplex R&D Systems
Matrix metallopeptidase 2 (MMP2) Multiplex R&D Systems
Matrix metallopeptidase 7 (MMP7) Multiplex R&D Systems
Matrix metallopeptidase 8 (MMP8) Multiplex R&D Systems
Matrix metallopeptidase 13 (MMP13) Multiplex R&D Systems
Leptin (LEP) Multiplex R&D Systems
Tyrosine kinase (TEK) Multiplex R&D Systems
Vascular endothelial growth factor-A (VEGF-A) Multiplex R&D Systems
Hepatocyte growth factor (HGF) Multiplex R&D Systems
Growth hormone 1 (GH1) Multiplex R&D Systems
Interleukin-1 alpha (IL1A) Multiplex R&D Systems
Interleukin-1 beta (IL1B) Multiplex R&D Systems
Epidermal growth factor (EGF) Multiplex R&D Systems
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SUPPLEMENTAL APPENDIX 3. EXTENDED STATISTICAL METHODS
a. Pooling of results across the 20 imputed data sets
For univariate or single-biomarker models, we applied Rubin’s rules to pool results across 
the 20 imputed data sets [1].
To avoid the LASSO to select different variables in each of the imputed data set, we 
estimated regression coefficients after pooling the imputed data sets into one ‘stacked’ 
data set. Since the LASSO does not involve the estimation of standard errors of regression 
coefficients, this is a valid approach to estimate the posterior modes of the regression 
coefficients, since in standard linear regression analyses posterior modes obtained by 
proper pooling and by a ‘stacked data’ analysis are approximately similar.
However, when the tuning parameter which controls the amount of restriction in the LASSO 
is optimized by cross-validation, the dependency of multiple data lines contributed by 
a single patient must be accounted for. Thus, our implementation of cross-validation 
involved leaving out all 20 imputed data lines of a patient simultaneously, and repeating 
this for each patient in turn. We validated this approach by comparing the such-optimized 
tuning parameter with the distribution of optimized tuning parameters obtained when 
each imputed data is analyzed separately. In addition, we compared the final number of 
selected variables in the pooled analysis with the distribution of selected variables across 
the 20 individual analyses (data not shown). We became aware of the existence of more 
sophisticated ways of applying the LASSO to multiply imputed data only after completing 
data analysis of this project [2].
b. Computation of predicted probabilities of accelerated eGFR function decline
From a predicted eGFR slope (Y) and its standard error for individual prediction (S), we 
derived the probability of accelerated eGFR decline (P), defined as a eGFR slope ≤ -3 mL/
min/1.73m2/year, as follows, making use of a normal approximation: P=F({-3-Y}/S), where 
F(z) denotes the cumulative distribution function of the standard normal distribution, 
evaluated at z. S was defined as the bootstrap estimate of the root mean squared 
error of prediction. The probabilities P are shown and compared between patients with 
accelerated and non-accelerated eGFR decline in Figure 2.
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Supplemental Figure 1. LASSO selection of established risk markers: cross validated mean squared 
error (Y-axis; black bullets; MSE) vs. amount of restriction (X-axis; log(Lambda)). Vertical bars refer to 
standard errors across the 82 cross-validations. Predictive accuracy reached a plateau after step 21 
(21st bullet from the right). At this step, the following established risk markers were selected: baseline 
UACR, current vs. never smoker, sex, systolic and diastolic blood pressure, use of oral diabetic 
medication, and baseline eGFR.
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ABSTRACT
Objectives: Micro- and macroalbuminuria are strong risk factors for progression of 
nephropathy in patients with hypertension or type 2 diabetes patients. Early detection 
of progression to micro- and macroalbuminuria may facilitate prevention and treatment 
of renal diseases. We aimed to develop plasma proteomics classifiers to predict the 
development of micro- or macroalbuminuria in hypertension and type 2 diabetes.
Methods: Patients with hypertension (n=125) and patients with type 2 diabetes (n=82) 
were selected for this case-control study from the PREVEND cohort and the Steno 
Diabetes Center. Cases transitioned from normo- to microalbuminuria or micro- to 
macroalbuminuria. Controls, matched for age, gender, and baseline albuminuria stage, 
did not transition. Follow-up was 3.0±0.9 years. Plasma proteomics profiles were 
measured by LC-electrospray-trap mass-spectrometry. Classifiers were developed and 
cross-validated for prediction of transition in albuminuria stage. Improvement in risk 
prediction was tested on top of a reference model of baseline albuminuria, eGFR, and 
renin-angiotensin-aldosterone system intervention.
Results: In hypertensive patients, the classifier improved risk prediction for transition 
in albuminuria stage on top of the reference model (C-index from 0.69 to 0.78; p<0.01). 
In type 2 diabetes, the classifier improved risk prediction for transition from micro- to 
macroalbuminuria (C-index from 0.73 to 0.80; p=0.04). In both diseases, the identified 
peptides were linked to pathways recognized to contribute to nephropathy, including 
fibrosis, inflammation, angiogenesis, and mineral metabolism.
Conclusions: Plasma proteomics predict the transition in albuminuria stage beyond 
established renal risk markers in hypertension or type 2 diabetes. External validation is 
needed to assess reproducibility.
INTRODUCTION
Hypertension and type 2 diabetes are the leading causes of progressive chronic kidney 
disease (CKD) [1]. Microalbuminuria (urinary albumin excretion (UAE) between 30 and 300 
mg/day) is considered a first sign of kidney dysfunction, and is an established and important 
predictor of progressive renal function loss in both hypertension and diabetes [2, 3].
Despite established therapies including renin-angiotensin-aldosterone system (RAAS) 
interventions, a substantial number of patients remain at risk for progressive loss of renal 
function [4, 5]. An explanation of this high residual renal risk might be that intervention 
is initiated after significant damage has already been established. Indeed, in the setting 
of RAAS intervention (RAASi), most risk reduction is observed when it is started in 
early stages of disease [6]. Thus, early detection of patients at risk to develop elevated 
albuminuria and subsequent initiation of appropriate treatment may be an efficacious 
approach to further reduce the incidence of end-stage renal disease (ESRD).
The identification of yet unknown biomarkers improving prediction of transitioning from 
normo- to microalbuminuria is currently a research priority [7]. Comprehensive analysis of 
peptides in biological fluids, known as peptidomics [8], has emerged as a tool to discover 
novel biomarkers at early stages of disease [9, 10]. Multiple peptides combined into one 
risk score may provide a tool to help classify which patients are at risk for progressive 
renal disease. 
Therefore, the aim of the current study was the identification of plasma peptides 
associated with transitioning in stage of albuminuria and to develop two classifiers, 
one for hypertension and another for type 2 diabetes, to predict the transition of stage 
of albuminuria.
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METHODS
This case-control study was performed utilizing plasma samples from patients 
participating in the community-based “Prevention of REnal and Vascular ENd-stage 
Disease” (PREVEND - http://www.prevend.org/) study and from patients seen at the 
Steno Diabetes Center. The ongoing PREVEND study was initiated in Groningen, the 
Netherlands, in 1997, to study the natural course of urinary albumin excretion with serial 
follow-up measurements [11]. At the Steno Diabetes Center in Gentofte, Denmark, a 
subgroup of patients was identified from a study initiated in 2007, which follows 200 
patients with type 2 diabetes with elevated urinary albumin excretion (UAE) (>30 mg/
day), normal plasma creatinine, and no known history of cardiovascular disease on a 
yearly basis [12]. Both the PREVEND and Steno Diabetes Center studies were approved 
by local ethics committees and were conducted in accordance with the guidelines of the 
Declaration of Helsinki. All patients gave written, informed consent. 
Hypertensive patients
Hypertensive patients were drawn from the PREVEND study. Hypertension was defined 
as the use of antihypertensive treatment (self-reported or by information retrieved from 
the regional pharmacy database) or a systolic/diastolic blood pressure >140/90 mmHg 
at baseline.
Type 2 diabetes patients
Patients with type 2 diabetes at baseline were drawn from both the PREVEND and the 
Steno Diabetes Center cohorts. For PREVEND patients, individuals with type 2 diabetes, 
defined as the use of oral glucose-lowering treatment (self-reported or by information 
retrieved from the regional pharmacy database), a fasting plasma glucose >7.0 mmol/l 
(126 mg/dl) or non-fasting plasma glucose >11.1 mmol/l (>200 mg/dl) were eligible for the 
present study [13]. For the Steno Diabetes Center patients, type 2 diabetes was defined 
according to similar criteria.
Selection of cases and controls
Cases were defined as patients who, had any progression in albuminuria stage (transition 
from normo- to microalbuminuria or from micro- to macroalbuminuria) with at least a 
30% increase in UAE from baseline between two consecutive study visits. Controls 
were selected from patients who had stable normo- or microalbuminuria, respectively, 
during the same follow-up period. Cases and controls were matched for age, gender, 
baseline albuminuria class, and for the patients from the Steno Diabetes Center, also on 
duration of diabetes. For the patients from the PREVEND study, a case and a matched 
control had to be in the same baseline albuminuria stage during the same study visit 
period. Normoalbuminuria was defined as UAE <30 mg/24hr, microalbuminuria as UAE 
between 30 to 300 mg/24hr, and macroalbuminuria as UAE ≥300 mg/24hr. The use of 
anti-hypertensive RAASi medication was allowed, but the type of drug and its dose had 
to remain stable during the study period. Patients who discontinued RAASi medication or 
initiated new treatment during the follow-up period were excluded from this study.
In hypertension, 50 normo- to microalbuminuria case/control pairs and 25 micro- to 
macroalbuminuria case/control pairs were selected for biomarker discovery. However, due 
to insufficient sample availability, proteomics analysis was not possible for all samples. 
Therefore, plasma samples with sufficient quantity and quality were performed in 125 
patients with hypertension (35 complete pairs in normo- microalbuminuria and 17 complete 
pairs in micro- to macroalbuminuria, and 14 patients in normo- to microalbuminuria 
and 7 patients in micro- to macroalbuminuria without a partner). In type 2 diabetes 24 
normo- to microalbuminuria case/controls pairs and 21 micro- to macroalbuminuria 
case/controls pairs were selected for biomarker discovery. Due to insufficient sample 
availability, data from plasma proteomics analysis was not possible for all samples. 
Plasma samples with sufficient quantity and quality were available for 82 patients with 
type 2 diabetes (17 complete pairs in normo- microalbuminuria and 18 complete pairs in 
micro- to macroalbuminuria, and 8 patients in normo- to microalbuminuria and 4 patients 
in micro- to macroalbuminuria without a partner). The blood samples were centrifuged 
at 4°C directly after collection. The plasma was afterwards stored at a controlled –80°C. 
In the year 2010, the samples were thawed and divided into smaller aliquots, refrozen at 
–80°C before thawing for proteomic measurements. For the PREVEND study, samples 
were stored for median 6.8 [range 2.7 – 13.0] years. Samples from the Steno Diabetes 
Center were stored for approximately 3 years.
Measurements
Clinical, plasma, and urine chemistry measurements in PREVEND and at the Steno 
Diabetes Center were performed as previously described [11, 12].
Briefly, in the PREVEND study, during 2 outpatient office visits, blood pressure was 
measured in the supine position, every minute, over 10 and 8 minutes, respectively, with 
an automatic device (Dinamap XLModel 9300; Johnson-Johnson Medical Inc.,  Arlington, 
TX, USA). Systolic and diastolic blood pressure was calculated as the mean of the last 
two measurements of the two visits. Albuminuria status was based on the average of 
two consecutive-day measurements in 24hr urine collections, which was measured 
by nephelometry with a threshold of 2.3 mg/L and intra- and interassay coefficients of 
variation of 4.3% and 4.4%, respectively (Siemens, Munich, Germany). Plasma glucose 
and serum and urinary creatinine were measured by dry chemistry (Eastman Kodak, 
Rochester, New York, USA). For serum creatinine, the intra-assay coefficient of variation 
was 0.9% and inter-assay coefficient of variation was 2.9%.
In patients from the Steno Diabetes Center, blood pressure was measured in sitting 
position as the mean of three oscillometric measurements with an electronic blood 
pressure device (UA 779; A&D Instruments Ltd, Abingdon, UK). Albuminuria was 
determined by the average of three consecutive-day 24hr urine collections (Turbidimetry, 
Hitachi 912 system; Roche Diagnostics, Mannheim, Germany). Hemoglobin A1c (HbA1c) 
was measured by high-performance liquid chromatography (normal range: 4.1–6.4%, 
Bio-Rad Laboratories, Munich, Germany) [14] and serum creatinine concentration by an 
enzymatic method (Hitachi 912; Roche Diagnostics, Mannheim, Germany). 
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For patients from both PREVEND and the Steno Diabetes Center, estimated glomerular 
filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease 
(MDRD) study equation, using gender, age, race, and serum creatinine [15].
Proteomics analysis
The plasma samples were analyzed at University Hospital RWTH, Institute for Molecular 
Cardiovascular Research (IMCAR) (Aachen, Germany), using LC-electrospray-trap mass-
spectrometry. LC-MS-grade water was purchased from LAB-SCAN (Gliwice, Poland). 
LC-MS-grade acetonitrile was obtained from Honeywell (Seelze, Germany). HPLC-grade 
formic acid was purchased from Merck (Darmstadt, Germany). All other chemicals were 
obtained from Sigma-Aldrich (Hamburg, Germany).
Sample Preparation
The plasma samples were thawed and centrifuged at 13,000×g for 2 minutes, in order to 
remove denatured proteins. An aliquot of 400µL was transferred into a new sample tube 
and 1µg of the internal standard ([Sar 1, Thr 8]- angiotensin II) was added to each sample 
[16]. Next, the samples were deproteinized by using perchloric acid. After addition of the 
acid, the samples were vortexed for 30 seconds and centrifuged at 8,000×g at 4°C for 2 
minutes. The supernatant was transferred into a new sample tube, and the pH value was 
adjusted at 9 or higher using 15M potassium hydroxide. The samples were vortexed for 
30 seconds and frozen at –80°C for 24hr. After thawing, the samples were centrifuged at 
3000×g at 4°C for 10 minutes. The supernatant was transferred into a new sample tube 
and stored at –80°C until fractionation.
Sample Fractionation Using Reverse-Phase-Chromatography
The samples were diluted in 5mL 0.2% formic acid and transferred into a sample loop 
for fractionation. The separation was performed on C18-“Chromolith”® Performance 
Reversed-Phase column (100mm×4.6mm Merck, Darmstadt, Germany). The mobile 
phase consisted of 0.2% formic acid in water (v/v) (eluent A) and 80% ethanol in water 
(v/v) (eluent B). The flow rate was 1mL/min. The total run time was 37.5 min. The following 
step gradient was used for the separation: 0-6 min 0%B, 6-14 min 20%B, 14-22 min 
40%B, 22-27 min 60%B, 27-29.5 min 100%B, 29.5-37.5 min 60%B. The samples were 
detected by using UV absorbance at 280nm. The 20% step-fraction, which contained the 
hydrophilic peptides of interest, was collected and lyophilized to dryness and used for 
further analysis.
Sample Analysis Using Electrospray Ionization Source-Liquid Chromatography Mass 
Spectrometry
All analyses were performed using an Agilent 1200 series HPLC (Böblingen, Germany), a 
liquid chromatographic system, interfaced to HTC mass spectrometer (Bruker-Daltonic, 
Bremen, Germany), equipped with an electrospray ionization source. The lyophilized 
sample (20% step-fraction) was re-suspended in 50µL 0.1% formic acid and 2µL were 
injected on the column for analysis. The samples were separated on a Zorbax SB C18 
Aq column (150mm×0.5mm, 5µm, Agilent Technologies, Santa Clara, USA). The column 
temperature was maintained at 50°C. The mobile phase consisted of 0.1% formic acid in 
water (v/v) (eluent A) and 0.1% formic acid in acetonitrile (v/v) (eluent B). The flow rate was 
60µL/min. The following gradient was used for the separation: 0-8.0 min 0-30%B, 8.0-11.5 
min 30-100%B, 11.5-13.5 min 100%B , 13.5–14.0 min 100-0%B, 14.0-20.0 min 0%B. 
The electrospray ionization source was set in positive ion mode. The ion spray voltage 
was set to 4,000V. The dry temperature was set at 300°C and the dry gas at 8 l/min. The 
nebulizer gas was set at 20psi. The maximal accumulation time was set to 200ms. The 
mass spectrometer was tuned on m/z 800 in wide mode. The mass spectrometer was 
operated in enhanced mode to achieve maximal resolution and mass accuracy. The scan 
range was 100-1500 m/z. All data were acquired and processed using Compass 1.3 
Software (Bruker-Daltonik, Bremen, Germany).
Data Pre-Processing
All acquired LC-MS raw data was pre-processed by using “Data-analysis” software 
(Bruker-Daltonik, Bremen, Germany). Therefore, an algorithm was used to select high 
quality signals (molecular features). The parameters used for filtering the data were as 
follows: signal-to-noise ratio: 3; correlation coefficient threshold: 0.7; minimum compound 
length: 10 spectra; smoothing width: 2. Furthermore, a spectral background subtraction 
was performed. To further simplify the data set for statistical analysis, the data was 
transferred to buckets using following parameters: 0.3 seconds and 0.3 m/z by using an 
profile analysis software (Bruker-Daltonik, Bremen, Germany). The data were normalized 
using the internal standard.
Statistical analysis
Analyses were performed with SAS software (version 9.3; SAS Institute, Cary, NC) and 
R version 2.12.2 (R Core Team 2012, Vienna, Austria) using the package glmnet [17]. A 
logistic regression analysis of a case-control study to evaluate the prognostic importance 
of a cross-validated classifier score with 50 cases and 50 controls will have approximately 
80% power to detect an odds ratio of 2 per standard deviation of the classifier at a two-
sided significance level of 5%, if adjusted for another strong confounding variable (odds 
ratio of 2 per standard deviation) which exhibits a correlation coefficient of 0.3 with the 
classifier. Given the assumptions used for sample size calculation, we would expect a 
C-index of 0.66 for the confounder-only model, and a C-index of 0.75 for confounder 
plus classifier model  [18]. Due to some samples missing, the achieved power was 
88% in hypertension and 70% in type 2 diabetes, given the same assumptions as the 
power calculation. 
Data are presented as mean and standard deviation for normal distributions, 
characteristics with skewed distribution are reported as median and 1st and 3rd quartiles, 
and categorical variables are reported as frequencies and percentages. Logarithmic 
transformation of UAE and peptide values was used to normalize their distributions 
and were used in all regression analyses. Differences between cases and controls 
were tested with independent samples t-tests for continuous variables and χ² tests for 
categorical variables. All p-values were two-tailed, and values <0.05 were considered 
statistically significant. 
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A classifier for hypertension and a separate classifier for type 2 diabetes, consisting of 
multiple molecular features combined into one risk score, were generated with the following 
steps. Mass-signals were extracted from about 10,500 mass-spectra accumulated from 
each group. Identifiable molecular features with a minimum of 12.5% non-zero values 
were selected for further analysis. Least absolute shrinkage and selection operator 
(LASSO) logistic regression models were fitted separately to the hypertensive and 
diabetic patient cohorts to select molecular features and estimate regression coefficients 
for the selected features [19]. Plasma-proteomic classifier scores were computed for 
each patient by internal leave-one-pair-out cross-validation. The hypertensive classifier 
was developed and cross-validated only within hypertension, and likewise, the type 2 
diabetes classifier was developed and cross-validated only within type 2 diabetes. More 
details about development of the classifier can be found in Supplemental Appendix 1. 
Prediction analysis was then performed to determine whether the plasma proteomics 
classifier improved risk prediction for transition of stage of albuminuria. We used 
unconditional logistic regression since, despite matched case-control sampling, there 
were some patients without a partner because proteomics measurement was not possible 
for some samples. We first fitted a reference model including baseline UAE, baseline 
eGFR and RAASi. Controlling for baseline UAE and baseline eGFR served to equalize 
residual differences between cases and controls in these variables persisting even after 
matching. In addition, we adjusted for use of RAASi medication at baseline since the 
number of patients on these drugs in the type 2 diabetes group was imbalanced between 
cases and controls. The differences in the C-index (p-value based on the likelihood ratio 
test) and the integrated discrimination improvement (IDI) between the reference model 
and a model additionally including the cross-validated plasma proteomics classifier were 
calculated. Because there were no significant differences between cases and controls 
in other clinical risk factors including ethnicity, body mass index (BMI), blood pressure, 
duration of diabetes, follow-up time, total cholesterol, fasting glucose, and HbA1c, these 
variables were not considered in prediction models.
Peptide and pathway identification 
The molecular features selected for the classifiers were further identified by matrix-
assisted laser desorption/ionization (MALDI) time-of-flight/time-of-flight (TOF/TOF) 
mass-spectrometry, revaluated using Fourier transform-Orbitrap mass-spectrometry, 
and identified using the profile analysis approach. Identified molecular features were 
then mapped to pathways. Pathways were retrieved from PANTHER Pathway and the 
Kyoto Encyclopedia of Genes and Genomes. For metabolites, relevant enzymes were 
retrieved from the Human Metabolome Database, and these proteins were used for 
pathway retrieval. Based on literature mining, the resulting pathway list was divided into 




The baseline characteristics of patients with hypertension (n=125) stratified by baseline 
stage of albuminuria (normo- or microalbuminuria) are shown in Table 1. We observed a 
significant difference in the baseline UAE level between hypertensive cases and controls 
despite the matching for albuminuria stage (Table 1). Furthermore, eGFR was lower in 
hypertensive cases compared to controls, but only in patients with macroalbuminuria at 
baseline this difference was statistically significant (Table 1). There were no significant 
differences in other baseline characteristics. The follow-up period for cases and controls 
was 3.1 ± 0.8 and 2.8 ± 0.9 years, respectively.
Hypertensive patients who transitioned from normo- to microalbuminuria or from micro- 
to macroalbuminuria had a median percentage increase in albuminuria of 281.9% [129.0, 
526.9] and 373.4% [188.7, 717.9], respectively. In hypertensive controls with baseline 
normo- or microalbuminuria, median changes in albuminuria were -0.2% [-22.4, 18.5] and 
37.8% [-1.3, 63.2], respectively (Table 1).
Overall performance of the model in hypertension
In hypertension, 37 molecular features were selected for the hypertension classifier 
(Supplemental Table 1). The values of the hypertension classifier were significantly 
higher in cases than in controls (0.97 ± 3.09 vs. -1.40 ± 3.30, p<0.01) (Figure 1a). The 
hypertension classifier was independently associated with transitioning in stage of 
albuminuria (Odds ratio 1.29, 95% CI=1.13-1.48, p<0.01). Additionally, the hypertension 
classifier improved risk prediction for transitioning in stage of albuminuria on top of the 
baseline model (C-index from 0.69 to 0.78, p<0.01; IDI 0.06, p=0.03) (Figure 1b). We 
did not identify effect modification by baseline albuminuria stage, suggesting that the 
predictive performance of the classifier was similar in both normo- to microalbuminuria 
and micro- to macroalbuminuria subgroups.
Type 2 diabetes
Baseline characteristics
The baseline characteristics patients with type 2 diabetes (n=82) stratified by baseline 
stage of albuminuria (normo- or microalbuminuria) are shown in Table 2. No differences 
were observed in baseline characteristics between cases and controls except in baseline 
UAE level between cases and controls (Table 2). There were no differences in eGFR 
between cases and controls (Table 2). The follow-up period for cases and controls was 
3.1 ± 1.0 and 2.9 ± 0.8 years, respectively.
Patients with type 2 diabetes who transitioned from normo- to microalbuminuria and from 
micro- to macroalbuminuria had a median percentage increase in albuminuria of 122.5% 
[101.1, 206.6] and 394.9% [200.3, 891.6], respectively. Type 2 diabetes controls with 
baseline normo- or microalbuminuria had a median percentage change in albuminuria of 
1.2% [-17.8, 22.1] and -11.6% [-35.8, 69.7], respectively.
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Figure 1a. Box-plot of cross-validated plasma proteomics classifier and transition in stage of 
albuminuria in patients with hypertension (n=125).
Figure 1b. C-index for prediction of transition in stage of albuminuria in patients with hypertension 
(n=125) for a) baseline UAE, baseline eGFR, RAASi (reference model) (C-index = 0.69) and b) cross-
validated plasma proteomics classifier on top of reference model (C-index = 0.78; p <0.01 compared 
to reference model).
Figure 2a. Box-plot of cross-validated plasma proteomics classifier and transition in stage of 
albuminuria in patients with type 2 diabetes with microalbuminuria at baseline (n=40).
Figure 2b. C-index for prediction of transition from micro- to macroalbuminuria stage in patients 
with type 2 diabetes (n=40) for a) baseline UAE, baseline eGFR, RAASi (reference model) (C-index = 
0.74) and b) cross-validated plasma proteomics classifier on top of reference model (C-index = 0.80; 
p = 0.04 compared to reference model).
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Overall performance of the model in type 2 diabetes
In type 2 diabetes, 18 molecular features were selected for the type 2 diabetes classifier 
(Supplemental Table 2). The values of the type 2 diabetes classifier were not significantly 
different between the cases and controls (-0.17 ± 2.2 vs. -0.87 ± 2.48, p=0.18). 
Additionally, the type 2 diabetes classifier was not independently associated with 
transition in albuminuria (Odds ratio 1.15, 95% CI=0.94-1.42, p=0.18). However, when 
testing an interaction term to assess whether the predictive performance was modified 
by baseline stage of albuminuria, the interaction was found to be significant (p-value 
for interaction = 0.04). In the normo- to microalbuminuria subgroup, the type 2 diabetes 
classifier was not associated with transitioning in stage of albuminuria (Odds ratio 1.21, 
95% CI=0.72-2.04, p=0.46). In contrast, in patients with microalbuminuria at baseline, 
the type 2 diabetes classifier was independently associated with transitioning in stage of 
albuminuria (Odds ratio 1.53, 95% CI=1.03-2.26, p=0.04). The type 2 diabetes classifier 
improved risk prediction for transitioning in stage of albuminuria in the microalbuminuria 
subgroup on top of the baseline model (C-index from 0.73 to 0.80, p=0.04; IDI 0.05, 
p=0.31) (Figure 2b).
Identification of molecular features and pathways in hypertension and type 2 diabetes
The molecular features identified in hypertension were linked to mechanisms that are 
recognized to contribute to nephropathy including metabolic pathways, intracellular 
signaling pathways (PI3K-Akt, MAPK, VEGF, Wnt, mTOR), angiogenesis, cytokine-cytokine 
receptor interaction, and ECM-receptor interaction. The molecular features identified in 
type 2 diabetes were associated to several pathways recognized to contribute to renal 
disease including metabolic pathways, signaling pathways (PI3K-Akt, VEGF, mTOR, 
MAPK, p38 MAPK), angiogenesis, pentose phosphate, and cytokine-cytokine receptor 
interaction. Figure 3 represents pathways recognized to contribute to nephropathy in 
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DISCUSSION
In this study we showed that newly developed plasma proteomics classifiers are able 
to predict transition in stage of albuminuria in hypertensive patients and transition 
from micro- to macroalbuminuria in patients suffering from type 2 diabetes. This was 
independent of established renal risk markers baseline UAE and eGFR, as well as used 
of RAAS intervention. The plasma peptides identified in hypertension and type 2 diabetes 
have been linked to pathways associated with established mechanisms of renal disease, 
including fibrosis, inflammation, angiogenesis, and mineral metabolism. Our findings 
suggest the use of these plasma proteomics classifiers as tools to identify patients with 
hypertension or type 2 diabetes at risk of renal disease progression in whom preventive 
treatment may be started in order to halt the devastating consequences of CKD.
Proteomics has been identified as a hypothesis-generating tool for biomarker discovery, 
though most proteomics studies of renal disease have focused on urinary proteomics 
[20-22]. For this study, we used plasma instead of urine. An advantage of plasma is that 
there are a higher numbers of substances compared to urine, so therefore there is a higher 
likelihood of detecting yet unknown biomarkers of CKD. Additionally, plasma still contains 
active mediators, in contrast to urine which is composed of metabolic waste products. 
There are a few proteomics studies on diabetic nephropathy conducted on blood-derived 
samples of patients with type 2 diabetes [23, 24], but none to our knowledge of studies 
on blood-derived samples for hypertensive renal disease. However, the aforementioned 
studies were conducted in serum, and peptides in serum have been shown to be subject 
to degradation due to high proteolytic activity immediately upon clotting [25]. The number 
of plasma proteomics studies is few. In a study of patients with type 1 or type 2 diabetes, 
twenty-eight unique plasma proteins mostly representing inflammatory response and 
coagulation proteins were identified for the screening and detection of diabetic retinopathy 
[26]. In a study conducted at the Steno Diabetes Center, ten single plasma peptides 
and three multi-peptide candidate biomarkers were identified for diabetic nephropathy in 
patients with type 1 diabetes ranging from having normoalbuminuria, microalbuminuria, 
and diabetic nephropathy [27]. However, these studies were cross-sectional in nature 
and did not evaluate the predictive value of plasma proteomics for disease progression. 
CKD is a complex disease involving many underlying pathophysiological mechanisms. 
Prolonged hyperglycemia in type 2 diabetes leads to chronic metabolic and hemodynamic 
changes that activate many intracellular signaling pathways, transcription factors, 
cytokines, chemokines, and growth factors that are implicated in diabetic nephropathy. 
The pathophysiology underlying hypertension is not fully known, but many mechanisms 
including signaling pathways, RAAS, and vascular inflammation and remodeling have been 
identified as fundamental mechanisms responsible for the development of hypertensive 
nephropathy. The hypertension and type 2 diabetes plasma proteomics classifiers 
included peptides that have been associated to several mechanisms contributing to renal 
disease. Peptides relating to fibrosis, a well-known pathologic feature of nephropathy 
resulting from expansion and change in composition of extracellular matrix in the kidney, 
were present in both classifiers. Peptides were related to PI3K-Akt, VEGF, mTOR, MAPK, 
and p38 MAPK signaling pathways points to a strong link to inflammation as a driver of 
progressive renal disease. Vascular endothelial growth factor A, a marker of angiogenesis, 
was observed in both hypertension and type 2 diabetes. An imbalance of angiogenesis-
related factors impeding the development of new blood vessels from pre-existing 
vasculature has been shown to be involved in the progression of CKD. Finally, activation 
of the Wnt pathway suggests a role of mineral metabolism disorders, and studies have 
shown that vascular calcification is associated with renal disease [28].
The plasma peptides identified in hypertension did not overlap those found in type 2 
diabetes and vice versa. This suggests that there may be disease-specific expressions 
of peptides in both hypertension and type 2 diabetes, and this is quite likely since the 
underlying pathology is different in both diseases. However, the peptides identified in 
the diseases were associated with similar pathways that drive nephropathy as shown in 
Figure 3. The question remains whether the different peptides truly represent differences 
between hypertension and type 2 diabetes or if these differences are related to the small 
sample size and case-control study design. Whether the peptides identified are either 
involved in the causal pathway contributing to CKD progression, or are markers of its risk, 
or are merely the end-product of existing pathological processes, remains an important 
and unresolved question that requires further exploration and cannot be addressed by 
our study. Additionally, assessing for confounding between these peptides and other 
risk factors of renal disease was beyond the scope of this prediction study and requires 
additional etiologic studies. 
We additionally detected molecular features that were identified as amino acid sequences 
and included these features in the classifiers. We hypothesize that these molecular 
features are free amino acids and are not degradation products from sample processing 
since the signal intensity of these amino acids were different between cases or controls.
There are strengths and limitations to this study. One strength includes using a rigorous 
cross-validation approach with several nested cross-validation loops to avoid the reporting 
of over-optimistic model performance due to validation of our classifiers with the same data 
that was used for model development. All decisions made during model development were 
subjected to cross-validation. Limitations include a significant difference in the absolute 
values of UAE between cases and controls and in eGFR in the micro- macroalbuminuria 
group in hypertension, indicating that cases and controls were different at baseline. The 
imbalance in baseline UAE was unintended, and represents our best efforts in matching 
cases and controls with the same albuminuria range from the original cohorts. To control 
for the imbalance, we adjust for baseline albuminuria and baseline eGFR in our statistical 
models. Due to the early stage of disease being investigated and the strict criteria used 
for the matching of cases and controls, we were able to select only a limited number of 
patients from the original large PREVEND and Steno Diabetes Center cohorts, which 
limited statistical power. However, this is to the best of our knowledge, the first study to 
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investigate prediction of renal disease progression in hypertensive and type 2 diabetes 
patients using plasma proteomics. Additional limitations include the lack of information 
concerning level of exercise, insulin use, diet, and other medication type and dose. The 
plasma proteomics classifier identified now requires validation in larger cohorts, ideally in 
large, prospective cohort studies.
The results of this plasma proteomics study support the growing evidence of using 
peptidomic platforms as a strategy for risk stratification of renal disease. As advancing 
laboratory techniques become more and more realistic in clinical practice, the 
complementary use of peptidomic techniques as a tool to reduce the burden of renal 
disease complications represents a strategy to improve disease diagnosis, prognosis, 
and treatment. In conclusion, our findings provide some evidence that proteomics 
analysis of plasma samples could be used to improve renal risk assessment of patients 
with hypertension and patients with type 2 diabetes for the prediction of transition of 
stage of albuminuria beyond established renal risk markers. Validation in an external 
study is needed to assess the reproducibility of these results. 
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SUPPLEMENTAL APPENDIX 1. EXTENDED STATISTICAL METHODS
For both hypertension and type 2 diabetes, a separate plasma proteomics classifier was 
developed using regularized logistic regression in three steps. Log-base-2 transformed 
peptide values were used in all regression analyses. If a peptide did not exhibit any 
expression in a sample, it was treated as a ‘zero’ rather than a missing value. First, 
peptides with more than p% missing values across all samples were excluded. Second, 
the ‘zero’ values of a peptide were set to the minimum measured value of that peptide on 
the logarithmic scale minus a constant value of d. A least absolute shrinkage and selection 
operator (LASSO) logistic model was fitted to select molecular features,1 with the tuning 
parameter λ selected such that the cross-validated deviance was minimized. Third, 
the model was refitted using ridge logistic regression including two variables for each 
selected peptide: one binary variable distinguishing zero from non-zero measurements, 
and one continuous variable equal to the logarithm of the measured peptide expression. 
For zero measurements, this second variable was set to the mean logarithm of peptide 
expressions to maintain interpretability of the binary variable’s coefficient. The tuning 
parameters p% and d were selected among a few possible choices by a leave-one-
out cross-validation loop around the whole model building process. This optimization 
gave the final regression coefficients which are described in Supplemental Tables 1 & 2. 
Since an independent validation sample was not available, we calculated cross-validated 
linear predictor scores (referred to as the plasma proteomics classifier) by repeating the 
complete model development process, including re-tuning of p% and d and selection of 
peptides, each time leaving out in turn one pair or a pair and a sample without partner 
from the analysis, and using the estimated model information (selected molecular features 
and model coefficients) to estimate the cross-validated plasma proteomics classifier for 
the left-out patients. The so-obtained plasma proteomics classifiers then used for model 
validation in the original respective patient samples (hypertension and diabetes mellitus).
Reference. Supplemental Appendix 1
1. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal 
Statistical Society. Series B (Methodological). 1996;58(1):267-288.
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ABSTRACT
Objectives: Early detection of individuals with type 2 diabetes mellitus (T2DM) or 
hypertension at risk for micro- or macroalbuminuria may facilitate prevention and 
treatment of renal disease. We aimed to discover plasma and urine metabolites that 
predict the development of micro- or macroalbuminuria.
Methods: Patients with T2DM (n=90) and hypertension (n=150) were selected from the 
community-cohort PREVEND and the Steno Diabetes Center for this case-control study. 
Cases transitioned in albuminuria stage (from normo- to microalbuminuria or micro- to 
macroalbuminuria). Controls, matched for age, gender, and baseline albuminuria stage, 
remained in normo- or microalbuminuria stage during follow-up. Median follow-up was 2.9 
years. Metabolomics were performed on plasma and urine. The predictive performance 
of a metabolite for albuminuria transition was assessed by the integrated discrimination 
index (IDI).
Results: In patients with T2DM with normoalbuminuria, no metabolites discriminated 
cases from controls. In patients with T2DM with microalbuminuria, plasma histidine 
was lower (fold change [FC]=0.87, p=0.02) and butenoylcarnitine was higher (FC=1.17, 
p=0.007) in cases versus controls. In urine, hexose, glutamine, and tyrosine were lower 
in cases versus controls (FC: 0.20, p<0.001; 0.32, p<0.001; 0.51, p=0.006, respectively). 
Adding the metabolites to a model of baseline albuminuria and estimated glomerular 
filtration rate improved risk prediction for macroalbuminuria transition (plasma IDI=0.28, 
p<0.001; urine IDI=0.43, p<0.001). These metabolites did not differ between hypertensive 
cases and controls without T2DM.
Conclusions: T2DM-specific plasma and urine metabolites were discovered that predict 
the development of macroalbuminuria beyond established renal risk markers. These 
results should be confirmed in a large, prospective cohort.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) and hypertension are leading causes of progressive 
chronic kidney disease (CKD) and may lead to End-Stage Renal Disease (ESRD). Despite 
current, established therapies, many people with T2DM remain at risk for progressive 
renal function loss. Latest therapies including blockade of the Renin-Angiotensin-
Aldosterone-System (RAAS) show significant risk reduction in late stage of disease [1]. 
However, most reduction in absolute and relative risk is observed when RAAS-intervention 
is tested in earlier stages of disease [2]. Microalbuminuria is considered the first sign of 
kidney dysfunction, often progressing to macroalbuminuria and ESRD [3,4]. Thus, early 
detection of individuals with T2DM at risk for micro- or macroalbuminuria by means of 
novel biomarkers and subsequent appropriate treatment may represent an effective 
strategy to reduce the incidence of ESRD.
Metabolomics, i.e. the measurement of low-weight intermediates and end-products of 
cellular functions in biological fluids, has emerged as a valuable tool to discover novel 
biomarkers for renal disease and in studying the pathophysiology of CKD [5]. The 
metabolome integrates the biological information of the genome, transcriptome, proteome, 
and overall enzymatic reactions of an individual, therefore enabling the detection of short 
and long-term physiological or pathological changes occurring in diseases. 
A recent review by Zhao (2013) gives concise highlights of metabolomics applications in 
CKD [6], but there are a limited number of metabolomics studies in humans where T2DM 
is the etiology of CKD. One cross-sectional study found panels of plasma metabolites 
associated with different CKD stages of renal impairment [7]. However, the study was 
conducted in patients without diabetes. In a study conducted in patients with T2DM, 
serum metabolites were identified that were able to distinguish between diabetic 
nephropathy with macroalbuminuria and diabetic patients without albuminuria [8]. Another 
study showed that there were significant differences in serum metabolite levels of leucine, 
dihydrosphingosine, and phytosphingosine in patients with diabetic nephropathy from 
T2DM patients without nephropathy or healthy controls [9]. Additionally, a panel of 13 
urine metabolites linked with mitochondrial metabolism was shown to be significantly 
reduced in diabetic CKD patients compared to healthy controls [10]. However, the cross-
sectional design of these studies did not enable assessment of the predictive value of the 
metabolites, and to our knowledge, there have been no published, longitudinal, clinical 
studies assessing the ability of metabolomics to predict progressive renal function loss 
in people with T2DM. 
Therefore, the aim of the current study was to discover potential metabolites that could 
predict the progression of renal dysfunction in T2DM. To test whether the metabolites 
were T2DM-specific, the same metabolites were tested in individuals with hypertension 
without T2DM.
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METHODS
Study participants and methods
This prospective, case-control study was performed utilizing samples from individuals 
participating in the community-based “Prevention of REnal and Vascular End-stage 
Disease” (PREVEND) study in the Netherlands or who were seen at the Steno Diabetes 
Center in Denmark. A detailed description of these studies has been previously 
described [11,12]. 
Median follow-up was 2.9 years [interquartile range: 2.5-4.0]. T2DM was defined as the 
use of oral glucose-lowering treatment (self-reported or by information retrieved from 
the regional pharmacy database), a fasting plasma glucose >7.0 mmol/L, or non-fasting 
plasma glucose >11.1 mmol/L. Hypertension was defined as the use of antihypertensive 
treatment (self-reported or by information retrieved from the regional pharmacy database) 
or a systolic/diastolic blood pressure >140/90 mmHg. Study participants with albuminuria 
measurements during follow-up, and plasma and urine samples of sufficient quality, were 
eligible for selection for the present study. Both the PREVEND and Steno studies were 
approved by their local ethics committees and were conducted in accordance with the 
guidelines of the Declaration of Helsinki. All participants gave written, informed consent.
Selection of cases and controls
Cases were defined as individuals who transitioned from normo- to microalbuminuria 
or from micro- to macroalbuminuria between two consecutive study visits with at least 
a 30% increase in urinary albumin excretion (UAE) from baseline. For each case that 
showed a transition in albuminuria stage, a matched control on T2DM or hypertension, 
age, gender, and baseline albuminuria stage (i.e. normoalbuminuria or microalbuminuria 
stage) was selected that most optimally resembled the case on these combined 
parameters. Steno patients were additionally matched for duration of diabetes. 
Normoalbuminuria was defined as UAE <30 mg/24hr, microalbuminuria as UAE = 30-300 
mg/24hr, and macroalbuminuria as UAE ≥300 mg/24hr. Albuminuria status was based 
on the average of 2 consecutive measurements in 24-hour urine collections. The use 
of anti-hypertensive agents intervening in the RAAS was allowed, but the type of drug 
and dose had to remain stable during the study period. Individuals who discontinued 
or initiated new RAAS treatment during the follow-up period were excluded from this 
study. The final T2DM sample consisted of 24 normo- to microalbuminuria case/controls 
pairs (all from the PREVEND study) and 21 micro- to macroalbuminuria case/controls 
pairs (8 pairs from the PREVEND study and 12 pairs from the Steno cohort). The final 
hypertension sample included 50 normo- to microalbuminuria case/control pairs and 25 
micro- to macroalbuminuria case/control pairs (all from the PREVEND study).
Measurements
Clinical, plasma and urine chemistry measurements in PREVEND and Steno were 
performed as described previously [12,13]. Estimated glomerular filtration rate (eGFR) 
was calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) study 
equation [14].
Metabolomic analysis
Urine samples were derived from 24-hour urine collections and stored in aliquots at minus 
20°C. Plasma samples were stored at minus 80°C. All samples were stored for 2-5 years 
and underwent one freeze-thaw cycle. Metabolomics were performed only on baseline 
samples. The samples were prepared as previously described [15] and randomized on the 
plate prior to analysis to avoid potential confounding interaction between concentration 
and order of injection and to ensure a homogenous between-plate design in regard to 
study groups. Measurements on plasma and urine samples were performed blinded by 
Biocrates Life Sciences AG (Innsbruck, Austria). A concise summary of metabolomic 
analysis can be found in Supplemental Materials: Metabolomic Methods. 
Acylcarnitines, glycerophospholipids, sphingomyelins, amino acids, hexoses and 
biogenic amines were analyzed in plasma und urine, whereas bile acids, eicosanoids 
and intermediates of energy metabolism were measured only in plasma.  All methods 
have been validated considering FDA guidelines [16]. A total of 277 plasma and 234 urine 
metabolites were identified.  
Statistical analysis
Analyses were performed using SAS version 9.2 and R version 2.14.0 (2011-10-31). 
Observations with missing data on covariates were not included. Baseline characteristics 
with normal distribution were reported as mean and standard deviation (SD), characteristics 
with skewed distribution were reported as median and inter quartile range [IQR], and 
categorical variables were reported as number and percentage. Variables with skewed 
distribution were log-transformed for regression analyses. Graphical methods were used 
to visualize normalization of the distribution after transformation. 
Differences between case/control pairs were tested with independent samples t-tests 
for continuous variables and χ² tests on paired proportions for categorical variables. 
The median analytical variance of quality control (QC) samples was 8.4% within-plate 
coefficient of variation (CV) and 11.6% between-plates CV for plasma measurements and 
8.5% within-plate CV and 12.0% between-plates CV for urine measurements. A total of 
12 plasma and 3 urine metabolites were below the detection limit in >70% of participants 
and therefore not included in the analysis. Remaining concentration values of 265 plasma 
and 231 urine metabolites were quantified, log2-transformed, and batch corrected [17]. 
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Differences in metabolite concentrations between cases and controls were tested with 
moderated F- and subsequent pairwise moderated t-tests [18]. Resulting p-values were 
corrected for multiple testing by false discovery rate [19]. All analyses were adjusted 
for baseline UAE and eGFR due to significant differences between cases and controls 
among these measurements. Conditional logistic regression was performed to investigate 
the association between metabolite concentrations and transition in albuminuria 
stage. Metabolites with significance of p-value <0.05 were used for prediction models. 
Additionally, the correlations of the metabolites with changes in UAE and eGFR were 
tested by linear regression analysis. Changes in albuminuria between follow-up and 
baseline were calculated as the logarithm of their ratio.
In order to determine whether the metabolites at baseline improved prediction of risk 
for albuminuria progression, the differences in the area under the receiver operating 
characteristic curve (AUROC) and the integrated discrimination improvement (IDI) were 
assessed by adding the metabolites to a reference model on top of baseline UAE and 
baseline eGFR) [20]. Because there were no significant differences between cases and 
controls in other clinical risk factors including ethnicity, body mass index (BMI), blood 
pressure, duration of diabetes, follow-up time, total cholesterol, fasting glucose, and 
glycated haemoglobin (HbA1c), these variables were not used in prediction models.
RESULTS
Type 2 diabetes mellitus
Baseline characteristics
In total, 45 T2DM case/control pairs were available for analysis. Baseline characteristics of 
T2DM cases and controls are shown in Table 1. Despite matching for baseline albuminuria 
stage, a significant difference in the absolute value of baseline UAE between T2DM cases 
and controls persisted in both subgroups (Table 1). Furthermore, eGFR was higher in 
T2DM controls than in the respective cases, but only in the micro- to macroalbuminuria 
subgroup was this difference statistically significant (Table 1).
T2DM cases with normo- or microalbuminuria had a median percentage increase in 
albuminuria of 142.1% and 340.9%, respectively. T2DM controls with baseline normo- or 
microalbuminuria had a median percentage change in albuminuria of 1.2% and -8.2%, 
respectively.
Differences in metabolite concentrations between cases and controls in T2DM
No metabolites were found to differ significantly between T2DM cases and controls 
in the normo- to microalbuminuria subgroup after correcting for multiple testing and 
adjusting for baseline UAE and eGFR. There were significant differences in metabolite 
concentrations only in the micro- to macroalbuminuria subgroup (Table 2). Therefore, 
we focused our further analysis on the micro- to macroalbuminuria subgroup. Figure 1 
presents exemplary chromatograms for these metabolites. In plasma, butenoylcarnitine 
was significantly higher (fold change 1.17, p=0.007, Figure 2a) whereas histidine was 
significantly lower (fold change 0.87, p=0.02, Figure 2b) in cases compared to controls. 
In urine, concentrations of hexose (fold change 0.20, p<0.001, Figure 3a), glutamine (fold 
change 0.32, p<0.001, Figure 3b), and tyrosine (fold change 0.51, p=0.006, Figure 3c) 
were significantly lower in cases compared to controls. 
Predictive performance of metabolites in T2DM for transition in albuminuria stage 
To assess the predictive performance of the selected biomarkers in the T2DM micro- to 
macroalbuminuria subgroup, we calculated the AUROC and IDI of a reference model 
consisting of baseline UAE and eGFR (AUROC=0.84). We then added the urine or 
plasma metabolites to the reference model. Addition of the plasma metabolites to the 
reference model resulted in an AUROC increase of 0.10 (p=0.02, Table 3) and an IDI of 
0.28 (p<0.001, Table 3). Addition of the urine metabolites to the reference model resulted 
in an AUROC increase of 0.15 (p=0.009, Table 3) and an IDI of 0.43 (p<0.001, Table 3). In 
terms of predictive performance, the combination of plasma and urine metabolites was 
not superior to the model containing the urine metabolites alone (not shown). 
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Figure 1. Exemplary extracted ion chromatograms (EIC) of histidine, glutamic acid and tyrosine in 
plasma and urine for T2DM cases (red) and controls (controls) in the micro- to macroalbuminuria 
subgroup. (a) EIC of histidine in plasma, (b) EIC of glutamine in urine, and (c) EIC of tyrosine in 
urine samples. As butenoylcarnitine and hexose were measured applying FIA-MS/MS (flow-injection 
coupled to mass spectrometry) no meaningful chromatogram is available for these metabolites.
Figure 2. Box plots of significant plasma metabolites corrected for multiple testing after adjusting for 
baseline UAE and eGFR. Concentrations of the two significant metabolites butenoylcarnitine (a) and 
histidine (b) in T2DM cases and controls in the micro- to macroalbuminuria subgroup are depicted 
in box plots.
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Figure 3. Box plots of significant urine metabolites corrected for multiple testing after adjusting for 
baseline UAE and eGFR. Concentrations of the three significant metabolites hexose (a), glutamine 
(b), and tyrosine (c) in T2DM cases and controls in the micro- to macroalbuminuria subgroup are 
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Table 4. Correlations between the significant plasma and urine metabolites with changes in UAE 
and in eGFR in patients with type 2 diabetes mellitus: Micro- to macroalbuminuria subgroup (n=42). 
β Coefficient Standard Error R2 p-value
Plasma
  Butenoylcarnitine vs. Delta UAE 1.4 0.55 0.14 0.02
  Butenoylcarnitine vs. Delta eGFR -15.9 6.1 0.15 0.01
  Histidine vs. DeltaUAE -1.5 0.60 0.13 0.02
  Histidine vs. Delta eGFR 8.0 7.1 0.03 0.26
Urine
  Glutamine vs. Delta UAE -0.22 0.10 0.12 0.03
  Glutamine vs. Delta eGFR 2.8 1.2 0.12 0.02
  Tyrosine vs. Delta UAE -0.15 0.12 0.04 0.22
  Tyrosine vs. Delta eGFR -0.67 1.4 0.01 0.63
  Hexose vs. Delta UAE -0.07 0.06 0.03 0.30
  Hexose vs. Delta eGFR 0.56 0.74 0.01 0.46
Delta UAE is measured as the log of the ratio between follow-up and baseline UAE values. 
Delta eGFR is computed as the difference between the follow-up and baseline eGFR values. 
Correlations of the metabolites with changes in UAE and eGFR in T2DM
In the T2DM micro- to macroalbuminuria subgroup, significant correlations were found 
between the metabolites and changes in UAE and eGFR during follow-up. In plasma, 
butenoylcarnitine correlated positively with changes in UAE, and negatively with changes 
in eGFR (p=0.02 and p=0.01, respectively, Table 4). Histidine was negatively correlated 
with changes in UAE (p=0.02, Table 4). In urine, glutamine was negatively correlated with 
changes in UAE and positively correlated with changes in eGFR (p=0.03 and p=0.02, 
respectively, Table 4). 
Hypertension
Metabolite concentrations in hypertensive cases and controls
In total, 75 hypertensive case/control pairs were available for analysis. The baseline 
characteristics of T2DM cases and controls are shown in Supplemental Table 1. 
Hypertensive cases who transitioned from normo- to microalbuminuria or from micro- 
to macroalbuminuira had a median percentage increase in albuminuria of 281.6% and 
373.4%, respectively. In hypertensive controls with baseline normo- or microalbuminuria, 
median changes in albuminuria were -2.6% and 40.5%, respectively (Supplemental Table 
1). The concentrations of the significant metabolites observed in the T2DM subgroup are 
listed in Supplemental Table 2 for the hypertensive population. No significant differences 
in these metabolites were observed between cases and controls with hypertension 
(Supplemental Table 2).
DISCUSSION
We found 3 urine and 2 plasma metabolites to predict progression from micro- to 
macroalbuminuria on top of established renal risk markers in T2DM. These metabolites 
did not predict albuminuria progression in hypertensive patients, suggesting a T2DM-
specific metabolite profile.
How do the specific metabolites relate to pathophysiological processes of T2DM? T2DM 
is characterized by a dysregulation of fatty acid, glucose, and amino acid metabolism 
induced by elevated lipid deposition in β-cells, liver and skeletal muscle [21,22]. 
First, regarding butenoylcarnitine, lipid deposition seems to contribute to insulin 
resistance and is associated with elevated plasma acylcarnitine concentrations [22]. 
Indeed, we found elevated concentrations of the acylcarnitine butenoylcarnitine in plasma 
of patients with T2DM who transitioned from micro- to macroalbuminuria. Acylcarnitines, 
especially short-chain acylcarnitine such as butenoylcarnitine, accumulate in plasma 
due to the excessive yet incomplete mitochondrial oxidation of fatty acids [22], possibly 
due to a lower mitochondrial number, volume, or reduced mitochondrial oxidation 
capacity in T2DM tissues [23]. Alteration in the acylcarnitine pattern has recently been 
demonstrated in a prospective study of patients with type 1 diabetes where a specific 
urinary acylcarnitine metabolite profile was able to clearly discriminate between patients 
who progressed in albuminuria stage after 5 years of follow-up; however, no plasma 
acylcarnitines were measured [24]. In a cross-sectional study in the general population, an 
inverse correlation was found between serum acylcarnitines and eGFR [25]. In agreement 
with this, we reported a negative correlation of plasma butenoylcarnitine with changes 
in eGFR in patients with T2DM. Additionally, butenoylcarnitine positively correlated with 
continuous changes in UAE indicating that butenoylcarnitine concentrations increase 
with progressive renal function loss. 
Second, we found lower concentrations of urinary glutamine in patients with T2DM who 
transitioned from micro- to macroalbuminuria. Glutamine is extracted by the kidney and 
metabolized to produce urinary ammonium [26]. Ammonia released by renal cells has 
been shown to normalize the diabetic-associated tubular acidotic milieu [26]. We may 
therefore speculate that observed decreases in urinary glutamine concentration may be 
due to the worsening of acidosis during progressive renal impairment. This hypothesis is 
supported by the finding that urinary glutamine was inversely correlated with changes in 
UAE during follow-up, pointing at glutamine as a candidate for future mechanistic studies.
Third, plasma histidine was significantly lower in patients with T2DM who transitioned from 
micro- to macroalbuminuria. Histidine has been shown to exert anti-inflammatory and 
anti-oxidant activity based on its ability to scavenge free radicals and to chelate divalent 
metal ions [27]. Plasma histidine concentrations were found to be significantly lower in 
CKD patients with signs of ongoing inflammation and associated with greater mortality in 
the same patients [28]. Dietary histidine supplementation seems to reduce oxidative and 
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inflammatory disease pathway, a strategy which holds promise in the treatment of renal 
disease [29]. A recent study demonstrated that albuminuria significantly correlated with 
oxidant and antioxidant marker levels in early diabetic nephropathy [30]. In agreement 
with this study, we found a negative correlation between the antioxidant marker histidine 
and changes in UAE during follow-up, suggesting that decreases in histidine may be also 
related to progressive renal dysfunction. 
Fourth, urinary tyrosine was significantly lower in T2DM micro- to macroalbuminuria 
cases versus controls. Tyrosine is a semi-essential amino acid that is only synthetized 
by the hydroxylation of phenylalanine by the enzyme phenylalanine hydroxylase (PAH). 
Chronic renal impairment is associated with decreased plasma concentrations of tyrosine 
whereas plasma concentrations of phenylalanine are often slightly increased, indicating 
impairment in the conversion of phenylalanine to tyrosine due to dysfunctional activity 
of PAH [31]. Moreover, PAH activity depends on the availability of its essential co-factor 
tetrahydrobiopterin (BH4), and underlying oxidative stress occurring in diabetes may limit 
BH4 availability and impair PAH activity [32]. Further studies are needed to investigate 
these possibilities in T2DM. 
Fifth, urinary hexose was decreased in patients with T2DM who transitioned from micro- 
to macroalbuminuria. However, the importance of hexose needs to be confirmed in larger 
cohort studies where correction for insulin and glucose concentrations is possible. 
An important question to be answered, especially in view of therapeutic purposes, is 
whether the metabolites are involved in the causal pathway leading to the disease (and 
its progression) or are merely the consequence of existing pathological processes. 
Several studies have shown that certain amino acids may be either a cause or a very 
early manifestation of insulin resistance that precedes the onset of diabetes by years 
[33]. Acylcarnitines may reflect the abnormal lipid metabolism in diabetes and have 
been shown to directly activate inflammatory pathways leading to inhibition of insulin 
action [34]. Inflammation contributes to lower plasma amino acid concentrations in CKD 
[35]. However, some amino acids such as histidine may directly affect inflammatory and 
oxidative pathways [28], indicating that alterations in those amino acids may represent a 
cause of chronic inflammation, oxidative stress, and progressive renal disease. As both 
inflammation and (lipid) oxidative stress caused by hyperglycemia seem to contribute 
to the pathogenesis of micro- and macroalbuminuria, we cannot exclude that the urine 
and plasma metabolites may also be a direct cause of albuminuria worsening over time. 
Indeed, some metabolites correlated significantly with changes in UAE during follow-up. 
The precise mechanisms of this process are currently not known but may involve the 
activation of some established pathways of renal damage such as nuclear factor kappa-
light-chain-enhancer of activated B cells (Nf-kB), protein kinase C (PKC) and mitogen-
activated protein kinases (MAPK) signaling pathways [36].
In our study, the urinary metabolome profile performed better than the plasma profile, and 
addition of the plasma metabolites to the urinary metabolites did not improve outcome 
prediction. This may point at urinary metabolomics as a better clinical approach to identify 
people with T2DM at risk of progressive renal disease (also due to practical advantages 
of collecting urine compared to blood samples). However, the results from the plasma 
metabolomics may be useful to identify underlying mechanisms and pathways of disease 
and should not be neglected.
The same study sample was recently used to validate the ability of a proteomic classifier 
to predict transition in albuminuria [13]. A direct connection between the proteome and 
metabolome in T2DM still needs to be determined. However, we did find similarities 
in the inflammatory profile (histidine in metabolomics vs. α-2-HS-glycoprotein and 
α-1-antitrypsin in proteomics), which supports the complementary use of proteomic and 
metabolomic techniques as a tool to reduce the burden of diabetes complications. One 
may interpret our results as if metabolomics is a stronger tool than proteomics due to 
the higher observed AUROC. It must be noted, however, that significant metabolites 
were observed only in the micro- to macroalbuminuria subgroup, whereas the 
proteomic classifier was significant in both normo- to microalbuminuria and micro- to 
macroalbuminuria subgroups. Importantly, in the micro- to macroalbuminuria subgroup, 
proteomics seemed to perform at best with an AUROC=0.99 (unpublished data).
There are limitations to this study. Due to the early stage of disease being investigated 
and the strict criteria used for matching cases and controls, we were able to select only 
a limited number of participants from the original large cohorts, limiting statistical power. 
Nevertheless, this is to our knowledge, the largest longitudinal discovery study to investigate 
prediction of renal disease progression in T2DM by means of metabolomic analysis. We 
are aware that these findings need to be validated in a larger prospective cohort. Nearly 
all clinical baseline variables were similar between cases and controls; however, there 
was a significant difference in the absolute values of UAE and eGFR between cases 
and controls. The imbalance in baseline UAE was unintended and represents our best 
efforts in matching cases and controls with the same albuminuria stage from the original 
cohorts. To account for this imbalance, we consistently adjusted our analysis for baseline 
UAE and eGFR. Another limitation was that the true predictive capacity of the models 
may be overestimated due to the relative high event rate which occurs in case-control 
studies and due to the prediction model being developed and tested in the same sample. 
Absolute values for the AUROC should therefore be interpreted with caution. The additive 
value of the metabolites to the AUROC of the reference model is however unaffected by 
the case-control design of the study. Additional limitations include the lack of information 
concerning the insulin-state, diet, and medication type and dose, which clearly represent 
unmeasured confounders in our study. 
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In conclusion, we discovered T2DM-specific plasma and urine metabolites as potential 
biomarkers for prediction of progression from micro- to macroalbuminuria. These 
metabolites had significant value in addition to conventional renal risk markers, and 
may contribute to the early identification and treatment of individuals with T2DM at risk 
for progression of renal disease. Our results, if confirmed in larger prospective cohort 
studies, could eventually open the door for an omic-based risk assessment in primary 
prevention of renal disease in T2DM.
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SUPPLEMENTAL MATERIALS: METABOLOMIC METHODS
Amino acids, acylcarnitines, sphingomyelines, phosphtidylcholines, hexose, biogenic amines: 
The quantification of amino acids, acylcarnitines, sphingomyelins, phosphatidylcholines, 
hexose (glucose), and biogenic amines was performed using a AbsoluteIDQTM p180 kit 
[1]. The assay was based on PITC (phenylisothiocyanate)-derivatization in the presence of 
internal standards followed by FIA-MS/MS (acylcarnitines, lipids, and hexose) and LC/MS 
(amino acids, biogenic amines) using an API4000 QTrap® mass spectrometer (Applied 
Biosystems/MDS Analytical Technologies, Darmstadt, Germany) with electrospray 
ionization. Multiple reaction monitoring (MRM) detection was used for quantification 
applying the spectra parsing algorithm integrated into the MetIQ software (Biocrates Life 
Sciences AG, Innsbruck, Austria).
Eicosanoids and oxidized fatty acids (prostaglandins): Eicosanoids and other oxidized 
polyunsaturated fatty acids were extracted from samples with aqueous acetonitrile that 
contained deuterated internal standards. The metabolites were determined by HPLC-
tandem mass spectrometry (LC-MS/MS) with Multiple Reaction Monitoring (MRM) in 
negative mode using a API4000 QTrap® mass spectrometer with electrospray ionization 
(Applied Biosystems/MDS Analytical Technologies, Darmstadt, Germany). The LC-MS/
MS method used for the analytical determination of eicosanoids has been published [2].
Energy metabolism intermediates: For the quantitative analysis of energy metabolism 
intermediates (glycolysis, citrate cycle, pentose phosphate pathway, urea cycle) 
hydrophilic interaction liquid chromatography (HILIC)-ESI-MS/MS method in negative 
MRM detection mode was used. The MRM detection was performed using a API4000 
QTrap® tandem mass spectrometry instrument (Applied Biosystems/MDS Analytical 
Technologies, Darmstadt, Germany). The sample was protein precipitated and extracted 
simultaneously with aqueous methanol in a 96 well plate format. Internal standards 
(ratio external to internal standard) and external calibration were used for highly 
accurate quantitation. 
Bile acids: A reversed phase LC-MS/MS analysis method in negative MRM detection 
mode was applied to determine the concentration of bile acids in plasma and urine 
samples. Samples were extracted via dried filter spot technique in 96 well plate format. 
For quantification, internal standards and external calibration were applied. In brief, 
internal standards and 20 µL sample volume placed onto filter spots were extracted and 
simultaneously protein precipitated with aqueous methanol. These sample extracts were 
measured by LC-ESI-MS/MS with an AB SCIEX 4000 QTrap™ tandem mass spectrometry 
instrument (Applied Biosystems/MDS Analytical Technologies, Darmstadt, Germany) in 
negative MRM detection mode. 
LC-MS/MS data were quantified with Analyst 1.5.1 software (Applied Biosystems, 
Darmstadt, Germany) and finally exported for comprehensive statistical analysis.
References. Supplemental Materials
1. Biocrates Life Sciences AG. Research Products. AbsoluteIDQ p180 Kit. Available at http://
www.biocrates.com/products/research-products/absoluteidq-p180-kit. Last accessed 18 
November 2013.
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preparation and simultaneous quantitation of prostaglandins and lipoxygenase derived 
fatty acid metabolites by liquid chromatography-mass spectrometry from small sample 
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ABSTRACT
Objectives: Individual patients show a large variability in albuminuria response to 
Angiotensin Receptor Blockers (ARB). Identifying novel biomarkers that predict ARB 
response may help tailor therapy. We aimed to discover and validate a serum metabolite 
classifier that predicts albuminuria response to ARBs in patients with diabetes mellitus 
and micro- or macroalbuminuria.
Methods: Liquid chromatography-tandem mass spectrometry metabolomics 
was performed on serum samples. Data from patients with type 2 diabetes with 
microalbuminuria (n=49) treated with irbesartan 300mg/day were used for discovery. 
LASSO and ridge regression were performed to develop the classifier. Improvement in 
albuminuria response prediction was assessed by calculating differences in R2 between 
a reference model of clinical parameters and a model with clinical parameters and 
the classifier. The classifier was externally validated in patients with type 1 diabetes 
with macroalbuminuria (n=50) treated with losartan 100mg/day. Molecular process 
analysis was performed to link metabolites to molecular mechanisms contributing to 
ARB response.
Results: In discovery, median change in urinary albumin excretion (UAE) was -42% 
[Q25-Q75: -69 -  -8]. The classifier, consisting of 21 metabolites, was significantly 
associated with UAE response to irbesartan (p<0.001) and improved prediction of UAE 
response on top of the clinical reference model (R2 increase from 0.10 to 0.70; p<0.001). 
In external validation, median change in UAE was -43% [Q25-Q75: -63 - -23]. The 
classifier improved prediction of UAE response to losartan (R2 increase from 0.20 to 0.59; 
p<0.001). Specifically ADMA impacting eNOS activity appears to be a relevant factor 
in ARB response.
Conclusions: A serum metabolite classifier was discovered and externally validated to 
significantly improve prediction of albuminuria response to ARBs in diabetes mellitus.
INTRODUCTION
Intervention in the renin-angiotensin-aldosterone system (RAAS) has convincingly shown 
to delay progression of renal disease in patients with diabetes mellitus with elevated 
urinary albumin excretion (UAE) in several large trials. However, individual patients show a 
large variability in long-term renoprotective response, which is linked to a large variability 
in the short-term response in albuminuria and blood pressure [1]. Consequently, a 
considerable proportion of patients still have significant residual albuminuria, which may 
contribute to progressive renal function loss [2]. The reasons behind these individual 
differences in response to therapy are not completely understood, but are in part related 
to renal tissue-specific RAAS activity, dietary salt intake, or genetic background [3-7]. 
Identifying novel biomarkers that predict the albuminuria lowering response to RAAS 
intervention may improve the current “trial-and-error” approach to choosing the optimal 
therapy for treatment of patients with diabetes mellitus. This would mark a step further to 
implementation of personalized medicine.
Biomarker discovery has advanced significantly over the past years with the use of high-
throughput omics screening platforms. Omics profiling has emerged as a research area 
to expand beyond biomarker discovery to also unravel molecular pathways involved in 
disease pathophysiology. Integrating these data with clinical data may help give further 
insights in the underlying molecular mechanisms of drug response variability. Prospective 
metabolomics studies predicting disease progression in diabetes mellitus are becoming 
more common [8-10], but to our knowledge, there are to date no metabolomics studies 
for the prediction of drug response in diabetes mellitus.
Therefore, the aims of this study were to first discover and validate a serum metabolite 
classifier that predicts response in albuminuria to angiotensin II receptor blocker (ARB) 
therapy in patients with diabetes mellitus and micro- or macroalbuminuria, and secondly, 
to integrate the identified metabolites in a molecular process model capturing disease 
pathophysiology at the interface of drug mechanism of action to decipher the underlying 
molecular processes driving albuminuria response to ARB. 
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METHODS
Patients and study design
Serum samples from patients enrolled in two distinct clinical studies conducted at the 
Steno Diabetes Center (Gentofte, Denmark), assessing the albuminuria lowering effect of 
ARBs were used for the present study.
For the discovery cohort, we use data from a crossover clinical study in type 2 diabetes 
assessing the effect of the ARB irbesartan. This cohort has been previously described 
[11]. In short, 52 patients with type 2 diabetes, hypertension, microalbuminuria, and 
treated with antihypertensive medication were recruited for a double-masked randomized 
crossover trial. At inclusion, previous antihypertensive treatment was discontinued and 
replaced with bendroflumethiazide, 5 mg once daily, for the entire study. Following two 
months wash-out (baseline), patients were treated randomly with irbesartan 300, 600, 
and 900mg once daily. All treatment periods were of 10 weeks’ duration and consisted 
of an initial two-week dose titration period with irbesartan 300 mg once daily followed by 
eight weeks treatment with irbesartan 300, 600, and 900 mg once daily in random order. 
For the present study, patient data and metabolomics measurements were available for 
49 patients with type 2 diabetes with persistent microalbuminuria. For this discovery 
cohort, we defined the outcome of interest as percent change in UAE after twelve weeks 
of treatment of ibestartan 300 mg/day compared to baseline UAE.
For the external validation cohort, we used data from a clinical study in type 1 diabetes 
assessing the effect of the ARB losartan. This cohort has been previous described [12], 
and included patients with type 1 diabetes, hypertension, and diabetic nephropathy. 
After a four-week washout, the patients received 100 mg losartan once daily and were 
followed prospectively with a mean follow-up period of 36 months. For the present study, 
patient data and metabolomics measurements were available for 50 patients with type 
1 diabetes and  macroalbuminuria. For the validation cohort, we defined the outcome of 
interest as percent change in UAE from baseline to UAE after sixteen weeks of treatment 
of losartan 100 mg/day. In this cohort, GFR was measured by plasma clearance of 51Cr-
EDTA every six months.
We expected the treatment effect of irbesartan and losartan on albuminuria to be fully 
present after twelve weeks or sixteen weeks of treatment, respectively. We refer to this 
as the response period.
Metabolomics measurements
Serum metabolomics were measured by BIOCRATES Life Sciences (Innsbruck, 
Austria). Flow injection analysis and liquid chromatography-tandem mass spectrometry 
based targeted metabolomics measurements were performed on serum samples [13]. 
The full set of 185 metabolites from the following chemical classes were quantified: 
acylcarnitines, amino acids, biogenic amines, energy/sugar metabolism (Hexoses), 
lysophosphatidylcholines, phosphatidylcholines, and sphingomyelins.
Statistical analyses
Analyses were performed using SAS version 9.3. Baseline characteristics with normal 
distribution were reported as mean and standard deviation (SD), characteristics 
with skewed distribution were reported as median and inter quartile range [IQR], and 
categorical variables were reported as number and percentage. The natural log of UAE 
and log-2 of metabolite concentrations were used in all regression analysis.
Statistical modeling consisted of several steps using a previously described methodology 
for development of a classifier [14]. First, a least absolute shrinkage and selection operator 
(LASSO) regression model was fitted in the discovery cohort to the full metabolite set to 
select a subset of metabolites that best predicted UAE response to ARB therapy [15]. 
The LASSO is advantageous for small samples sizes because it places restrictions on 
the absolute sizes of the regression coefficients with a tuning parameter λ and controls 
for multicollinearity, thereby selecting the optimal subset of variables that best predicts 
the outcome. The tuning parameter was optimized by five-fold cross-validation, and 
bootstrap (N=1000) was used to evaluate selection probabilities of each metabolite. 
Next, the metabolites selected by the LASSO were refitted in a new model using ridge 
regression to generate the classifier. Cross-validation was performed to select a new 
tuning parameter for the ridge regression model that minimized the mean square error 
(MSE). Finally, the classifier was validated in an external cohort by applying the betas for 
each metabolite and the tuning parameter as estimated from the discovery cohort.
In both the discovery cohort and the validation cohort, the added value of the classifier 
was evaluated by deriving the explained variation of the model (R2) from the MSEs in 
order to determine whether the biomarkers significantly improved prediction on top of 
a model of baseline clinical parameters (age, sex, HbA1c, SBP, GFR, UAE). The area 
under the receiver operating characteristics (ROC) curve and integrated discrimination 
improvement (IDI) index were calculated to assess the discriminatory ability of the serum 
metabolites for a dichotomous outcome of >30% decrease in UAE during the response 
period. This threshold was used based on prior work [2, 16, 17]. 
For the validation cohort, we also determined whether the serum metabolite classifier 
was able to predict change in GFR after the initial response period. Patient-specific GFR 
change was calculated by fitting a straight line through the GFR values after the initial 
response period, i.e. from week 16 to the end of follow-up using a linear regression model, 
as was done in the original study [12]. A dichotomous outcome for GFR change ≤ or > 
-3.0 mL/min/1.73m2/year was created to assess the discriminatory ability of the serum 
metabolites for accelerated renal function decline. The threshold of -3 mL/min/1.73m2 
was chosen based on prior studies [9, 18, 19] and was approximately the median GFR 
change in this cohort (-3.4 [Q25, Q75: -5.7, -1.4]).
Molecular model of ARB drug mechanism of action
Identification of protein coding genes showing association with ARB mechanism of action 
was performed by querying NCBI PubMed and gene2pubmed. For both drugs, a PubMed 
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search using the queries >>”irbesartan”[TIAB] OR irbesartan[nm]<< or >>”losartan”[TIAB] 
OR losartan[nm]<< was performed for identifying publications discussing irbesartan 
and losartan, respectively. Genes linked to identified publications were extracted from 
gene2pubmed. For irbesartan, 1471 publications associated to a total of 44 genes and 
for losartan 8166 publications linked to 101 genes in total were identified. The total set 
of 125 protein coding genes was used for deriving a mechanism of action molecular 
model as described in Heinzel et al. [20]. In short, molecular features were mapped on a 
human protein interaction network, and the induced subgraph was split into molecular 
process segments according to network topology. The resulting ARB mechanism of 
action molecular model holds 48 protein coding genes embedded in seven molecular 
process segments.
Interference of this ARB mechanism of action molecular model was performed with a 
previously identified diabetic kidney disease (DKD) molecular model holding 688 protein 
coding genes in 34 molecular process segments [21]. Interference was defined by an 
overlap of interacting protein coding genes being present in both the ARB mechanism of 
action molecular model and the DKD molecular model.
Assignment of metabolites
Metabolites selected for the classifier were assessed for being part of the DKD 
molecular model. Metabolite-to-enzyme assignments were identified utilizing the Human 
Metabolome Database (HMDB) and the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database. Of the 185 metabolites addressed in targeted metabolomics, 114 
metabolites could be assigned to at least one enzyme. The respective number for the 
shortlist of 21 metabolites included in the classifier on drug response is 14. For these 
14 metabolites, nine could be assigned to the molecular model representation of DKD 
involving 11 assigned enzymes. 
RESULTS
Baseline characteristics are presented in Table 1. In the discovery cohort, patients were 
approximately 59 (standard deviation 10) years of age, mostly male (80%), had a known 
duration of type 2 diabetes of 13 (8) years, and median 24-hour UAE was 84 [Q25, Q75: 
65, 200] mg/24hr. Median change in UAE was -42% [Q25, Q75: -69, -8] after twelve 
weeks of treatment of ibestartan 300 mg/day (Table 1). 
In the validation cohort, patients were approximately 47 (9) years of age, mostly male 
(60%), had a known duration of type 1 diabetes for 33 (9) years, and median 24-hour 
UAE was 1211 [Q25, Q75: 598, 2023] mg/24hr. Median change in UAE was -43% [Q25, 
Q75: -23, -62] over 16 weeks of treatment with losartan 100 mg/day (Table 1). During 
approximately three years of follow-up, GFR change after the response period was -3.8 
(3.6)  mL/min/1.73m2/year.
There were no significant associations between baseline characteristics and change in 
UAE in either the discovery or validation cohorts (Supplemental Table 1).








  Age (years) 59.0 (10.0) 44.6 (8.9)
  Male Sex (number (%)) 39 (80) 30 (60)
  SBP (mmHg) 140.0 (15.4) 150.6 (17.7)
  DBP (mmHg) 81.6 (8.8) 84.7 (10.9)
  HbA1c (%) 8.3 (1.4) 8.9 (1.2)
  HbA1c (mmol/mol) 67.2 (15.3) 73.8 (13.1)
  Cholesterol (mmol/l) 5.3 (1.0) 5.2 (1.0)
  HDL (mmol/l) 1.2 (0.3) 1.6 (0.5)
  GFR (ml/min/1.73m2) 102.3 (19.2) 86.5 (23.4)
  24-hour UAE (mg/24hr) 84 [65, 200] 1211 [598, 2023]
Follow-up
  Change in SBP (mmHg) -6.4 (16.2) -8.7 (14.3)
  Change in DBP (mmHg) -6.0 (8.8) -5.6 (8.6)
  Percent change in UAE (%) -42% [-69, -8] -43% [-62, -23]
  >30% decrease in UAE from baseline (number (%)) 31 (63) 34 (68)
  GFR change after response period  
  (mL/min/1.73m2/year)
not available -3.8 (3.6)
Data are reported as mean ± standard deviation (SD) or number (percent) or median [25th, 75th 
quartile].
Serum metabolite classifier
Out of the total set of 185 metabolites, 21 metabolites were selected with LASSO as best 
predictors of UAE response to ARB therapy in the discovery cohort. These 21 metabolites 
were used for the classifier. The 21 metabolites are presented in Supplemental Table 2. 
In the discovery cohort, the serum metabolites classifier was significantly associated with 
change in UAE in response to irbesartan 300 mg/day (p-value <0.001) and significantly 
improved prediction on top of clinical parameters (R2 increase from 0.10 to 0.70; p-value 
<0.001) (Figure 1A and 1B, Table 2). For the dichotomous outcome of >30% decrease 
in UAE during the response period, the control model area under the ROC curve was 
0.72, and the addition of the serum metabolite classifier significantly increased the area 
under the ROC curve to 0.95 (p-value = 0.001) (Table 2). The IDI of the classifier was 
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0.33 (p-value <0.001) (Table 2). The classifier improved prediction in SBP response (R2 
increase from 0.63 to 0.68; p-value = 0.019).
In the validation cohort, the serum metabolite classifier was significantly associated with 
change in UAE in response to lorsartan 100 mg/day (p-value <0.001) and significantly 
improved prediction of change in UAE on top of a panel of clinical parameters (R2 increase 
from 0.20 to 0.53; p-value <0.001) (Figure 1C and 1D, Table 2). For the dichotomous 
outcome of >30% decrease in UAE during the response period, the area under the ROC 
curve for the control model was 0.74, and the addition of the serum metabolite classifier 
increased the area under the ROC curve to 0.89. This increase was not significant (Table 
2). In The IDI of the classifier was 0.19 (p-value= 0.06) (Table 2). The classifier did not 
improve prediction in SBP response in external validation (R2 control = 0.24, R2 classifier 
0.25; p-value = 0.54).
Figure 1. Prediction of change in UAE from baseline. A) Discovery cohort, clinical parameters model; 
B) Discovery cohort, clinical parameters + serum metabolite classifier model; C) Validation cohort, 
clinical parameters model; D) Validation cohort, clinical parameters + serum metabolite classifier 
model. The lines of identity are shown in light grey, and the regression lines are shown in dashed 
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In the validation cohort, for prediction of GFR change after the response period, the 
combination of the 21 serum metabolites significantly improved prediction on top of 
clinical parameters (R2 increase from 0.15 to 0.60; p-value <0.001). For the dichotomous 
outcome for GFR change ≤ or > -3.0 mL/min/1.73m2/year, a significant increase was 
observed in the area under the ROC curve with the addition of the serum metabolites on 
top of clinical parameters (ROC increase from 0.71 (95% C.I. 0.57 – 0.86) to 0.88 (95% 
C.I. 0.79 – 0.98); p-value 0.010).
Metabolite assignment
To study the molecular mechanisms linked to albuminuria response and ARB effect, 
molecular process analysis was conducted by assigning the metabolites included in the 
classifier to enzymes and further to molecular processes identified in a DKD molecular 
model. The combined irbesartan/losartan drug mechanism of action molecular model 
holding 48 protein coding genes is presented in Figure 2A. The model interference of the 
ARB drug mechanism of action molecular model with the DKD molecular model is shown 
in Figure 2B. In total, 20 interacting protein coding genes being reported as associated 
with ARB effect were also identified in the DKD molecular model. Key overlap of ARB 
effect with DKD pathophysiology are shown in Figure 2C, at first including the drug target 
angiotensin II receptor, type 2 (AGTR2) together with the bradykinin system and the 
NFκB/PPARγ axis.
Nine out of the 21 metabolites included in the classifier could be assigned to 11 enzymes 
also involved in the DKD molecular model, including enzymatic turnover as well as 
metabolite transport. Metabolite-enzyme links are provided in Supplemental Table 3. 
Interference of ARB drug mechanism of action molecular model and the DKD molecular 
model identifies the enzyme nitric oxide synthase 3 (NOS3). The metabolites included 
in the classifier were assigned to NOS3 are asymmetric dimethylarginines (ADMA) 
and citrulline, with ADMA being the most frequently selected metabolite in the LASSO 
(Supplemental Table 2). Furthermore, overlap of enzymes at the molecular process 
level between the molecular models was observed involving amino acids (glutamine, 
asparagines and tryptophan), lysophosphatidylcholines (lysoPC a C16:0 and lysoPC a 
C16:1), and phosphatidylcholines (PC aa C36:0 and PC aa C42:2). This subset of seven 
metabolites assigned to direct drug-to-DKD interference (ADMA, citrulline) or to molecular 
processes  with interference on the molecular model level (lysoPC a C16:0, lysoPC a 
C16:1, PC aa C36:0, PC aa C42:2, tryptophan) significantly improved the explained 
variation in albuminuria response (R2) in the discovery study (R2=0.50; p<0.001 versus 
clinical model) and validation study (R2=0.39; p=0.001 versus clinical model).
Figure 2. A) Combined irbesartan/losartan drug mechanism of action molecular model holding 
48 protein coding genes (nodes) organized in seven molecular process segments (boxes). Protein 
interactions are indicated as edges, further interactions of proteins across process segments are 
omitted. B) Interference of ARB mechanism of action model on the DKD molecular model. Matching 
network segments are shown as red nodes. Nodes colored in blue identify enzymes associated with 
metabolites included in the classifier, nodes in pink indicate metabolite transport. C) Gene symbols 
for selected nodes matching in drug and DKD molecular models, and associated metabolites in case 
of enzymes according to Supplemental Table 3.
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DISCUSSION
This study discovered and externally validated a serum metabolite classifier that 
significantly improves prediction of albuminuria response to ARBs in patients with 
diabetes mellitus with micro- or macroalbuminuria on top of traditional clinical risk 
factors. Metabolites included in the classifier could be assigned to general molecular 
mechanisms of oxidative stress, inflammation, and fibrosis pathways. Specifically, NOS3 
activity appears to be a relevant factor in predicting the albuminuria lowering response to 
ARBs. Our findings suggest the use of serum metabolites as a tool to tailor albuminuria 
lowering ARB treatment and illustrate the use of metabolomics to unravel underlying 
molecular mechanisms of ARB response. 
Metabolomics, the measurement of exogenous or endogenous small molecules in a 
sample, is an emerging research area to identify novel biomarkers. The metabolome 
integrates the biological information of the genome, transcriptome, proteome, and 
overall enzymatic reactions of an individual, therefore enabling the detection of short and 
long-term physiological or pathological changes occurring in diseases [22]. Metabolomics 
can be used to unravel molecular pathways of biological processes in order to better 
understand disease progression [9, 23, 24], but to the best of our knowledge, this is the 
first study integrating metabolomics to study response to drug therapy. These types of 
studies are necessary to characterize the molecular mechanisms of drug effects and 
drug response variability.
Pharmacological blockade of angiotensin II activity by ARBs is currently the most widely 
used therapeutic option (next to angiotensin converting enzyme inhibitors) for treatment 
of hypertension and albuminuria in diabetes mellitus. Yet, approximately 25% of patients 
with diabetes mellitus do not respond in terms of albuminuria lowering to ARBs [1]. The 
serum metabolite classifier was able to predict the short-term albuminuria response to 
the ARBs. This observation is important from a therapeutic point of view as a poor anti-
albuminuric response predicts poor long-term renal prognosis [25]. Importance of early 
albuminuria reduction is not only evident for renoprotection but also for cardiovascular 
protection [2]. The metabolite panel thus provides an indication which patients will be 
protected for long-term renal and cardiovascular outcomes. In addition to predicting UAE 
response, the classifier predicted systolic blood pressure response in the discovery cohort 
but not in the validation cohort. The failure to predict the systolic blood pressure response 
may be explained by prior observations that not all patients respond concordantly in terms 
of albuminuria-lowering or SBP-lowering to ARBs [16, 17]. Identification and validation 
of novel biomarkers that can predict response to therapy may improve on the current 
“trial-and-error” approach in prescribing medication, may ultimately help reduce the large 
individual variability in response to therapy, and could be a step forward to implement 
personalized medicine.
We performed a molecular process analysis aiming to further unravel the molecular 
mechanisms linked to albuminuria response to ARBs in diabetes mellitus. The network 
approach assumes that individual drug response variability can be in part attributed to 
individual variability in underlying molecular mechanisms involved in the progression 
of disease in the light of personalized molecular pathophysiology. Indeed, coupled 
pathophysiological processes such as oxidative stress, inflammation, and fibrosis appear 
to drive disease progression, but the individual contribution of each process varies per 
individual. Drugs on the other hand, address specific targets and thereby interfere in 
specific disease associated processes. At this level, metabolites, or biomarkers more 
generally, may help to gain insight to which specific pathophysiological processes are 
driving disease progression and are targeted by a specific drug’s mode of action [26]. 
A key finding from the molecular process analysis is the relevance of nitric oxide (NO) 
in ARB response, as illustrated by the direct interference of ARB molecular mechanism 
of action and DKD molecular model by the enzyme NOS3, and further reflected by the 
inclusion of ADMA and citrulline in the serum metabolite classifier. ADMA, an endogeneous 
NO synthase inhibitor, is considered relevant in endothelial dysfunction contributing to 
extracellular matrix remodeling and being involved in inflammation [27]. Increased ADMA 
levels have been shown to contribute to increased risk of progressive diabetic kidney 
disease and predict fatal and nonfatal cardiovascular events in patients with type 1 
diabetic nephropathy [28]. The positive beta values for ADMA in the regression models 
suggest that higher concentrations of the metabolite are associated with less albuminuria 
reduction. We therefore speculate that higher concentrations of ADMA lead to increased 
blockade of NOS3, resulting in a decrease in NO availability and diminished albuminuria 
response. Furthermore, citrulline, catalyzed by NOS3, has been shown to be inversely 
correlated to inflammatory parameters such as C-reactive protein [29]. Supplementation 
with citrulline has been shown to increase arginine/ADMA ratio, in turn decreasing blood 
pressure and improving vascular function [30]. Our study points to higher concentrations 
of citrulline associated with greater reductions in albuminuria. ADMA and citrulline 
assignments in the drug molecular model and DKD molecular model further suggest that 
albuminuria response to ARBs is reflected on the background of progressive disease as 
well as influenced by eNOS activity.
Some metabolites in the classifier could not be directly linked to the ARB mechanism 
of action molecular model, but were linked to processes driving progression of kidney 
disease. This indicates that in order to assess drug response, the interplay between 
disease progression molecular characteristics and specific drug molecular effects should 
be considered. This notion was further emphasized when testing a different subgroup of 
metabolites. The subset of seven metabolites being present in the DKD molecular model 
and being linked with oxidative stress response, inflammation and fibrosis (TGFB and 
downstream ECM remodeling) next to NOS3 activity significantly improved prediction of 
albuminuria response. Furthermore, interferences at the process units at the direct drug 
target together with the bradykinin system and on NFκB/PPARγ indicate involvement 
of inflammatory processes and lipid metabolism contributing to ARB response. These 
observations suggest that for assessing drug response, both disease progression status 
and specific drug molecular effects need to be taken into account. Metabolites of the 
renin-angiotensin-system were not included in the classifier, suggesting that markers of 
RAAS activity do not predict the response to RAAS inhibition, which is in line with prior 
studies [31, 32].
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Within the validation cohort, we were able to assess GFR change after the initial response 
period up to the end of follow-up. We observed an improvement in GFR over follow-up 
in patients who had a >30% decrease in UAE from baseline, compared to a patients who 
did not see such a benefit in albuminuria response (Supplemental Table 4). This is in line 
with previous literature showing that greater reduction in albuminuria is associated with a 
lesser decline in eGFR during long-term follow-up [17]. Of interest, the metabolites were 
able to improve prediction of GFR changes, indicating that the serum metabolite classifier 
enables the identification of a group of patients who do not have a good albuminuria 
response to ARB therapy and have a fast deterioration of renal function over time. Further 
studies in large, diverse patient cohorts is necessary for validating these findings. 
Limitations of this study include lack of comprehensiveness of drug mechanism of action 
characterization. The combined losartan/irbesartan mechanism of action molecular 
model included a total of 48 protein coding genes retrieved from literature mining. Adding 
detailed omics profiling specifically on drug effect on kidney cells and tissue via in vitro 
or in vivo models would provide an improved representation of ARB molecular effect. In 
addition, the relative small sample sizes of the included trials may have decreased the 
precision of our effect estimates. Unfortunately, a type 2 diabetes validation cohort was 
not available. We therefore validated the metabolomics classifier in a type 1 diabetes 
cohort and demonstrated that the classifier was able to predict response to ARB therapy 
in this population as well. While the pathophysiology of the diseases are clearly different, 
the response to treatment and predictors of response may be similar. We showed that the 
classifier was able to predict the albuminuria response to two different ARBs.  Whether 
the classifier predicts the response to other interventions in the RAAS has to be analyzed 
in future studies. 
In conclusion, we discovered and externally validated a classifier of 21 serum metabolites 
that significantly improve prediction of albuminuria response to ARBs in diabetes mellitus. 
Metabolites included in the classifier were assigned to stress/inflammation pathways and 
downstream consequences of fibrosis and extra cellular matrix remodeling. Specifically, 
NOS3 activity appears to be a specific factor relevant in ARB response. These results 
indicate that for assessing drug response, both disease progression status and specific 
drug molecular effects need to be taken into account. Moreover, the results of this 
metabolomics study support the growing evidence of using omics tools as a strategy 
to improve molecular characterization of drug effect and disease pathophysiology. 
The complementary use of omics platforms, integrated into molecular process models 
and from there determining biomarker panels, makes implementation of personalized 
medicine increasingly realistic in clinical practice.
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β S.E. p-value β S.E. p-value
Age at baseline 0.58 0.53 0.281 0.8 0.9 0.386
Male sex 7.7 13.2 0.560 -24.9 15.2 0.109
Baseline SBP -0.02 0.4 0.961 0.5 0.4 0.257
Baseline DBP -0.6 0.6 0.362 0.2 0.7 0.788
Baseline HbA1c 1.6 3.9 0.683 7.1 6.3 0.264
Baseline Cholesterol -0.8 5.4 0.877 4.4 7.6 0.567
Baseline HDL 19.4 15.8 0.225 14.0 14.3 0.332
Baseline GFR -0.2 0.3 0.554 0.02 0.3 0.961
Baseline 24-hour logUAE -7.9 5.7 0.177 -12.6 9.1 0.174
Supplemental Table 2. LASSO-selection of best predictors. Results from LASSO regression 
of 21 metabolites selected for the serum metabolites classifier, 5-fold cross-validation, and 











Asymmetric dimethylarginine (ADMA) 4.4 6.5 0, 22 52.4
Asparagine (Asp) -3.0 7.4 -26, 0 26.2
Carnitine (C0) -2.4 6.8 -24, 0 20.0
Acylcarnitine (C12-DC) 11.3 24.6 0, 88 31.4
Linoleoylcarnitine (C18:2) -3.0 7.5 -27, 0 22.8
Acylcarnitine (C5:1-DC) 2.9 7.4 0, 25 23.4
Glutarylcarnitine (C5-DC / C6-OH) 3.3 7.5 0, 28 27.2
Acylcarnitine (C6:1) 3.7 9.9 0, 34 23.5
Acylcarnitine (C7-DC) 2.39 6.99 0, 25 20.6
Octanoylcarnitine (C8) -3.0 8.8 -31, 0 20.6
Citrulline (Cit) -2.0 4.9 -17, 0 27.5
Glutamine (Gln) 3.7 7.8 0, 28 31.8
Histidine (His) 7.5 14.0 0, 48 36.2
Lysophosphatidylcholines (lysoPC a C16:0) -10.4 18.4 -62, 0 36.9
Lysophosphatidylcholines (lysoPC a C16:1) -2.9 6.4 -22, 0 26.2
Phosphatidylcholines (PC aa C36:0) 4.5 7.0 0, 23 44.1
Phosphatidylcholines (PC aa C42:2) 9.7 13.8 0, 46 51.6
Symmetric dimethylarginine (SDMA) 0.3 1.0 0, 3 22.5
Spermine -3.9 7.0 -24, 0 36.2
Tryptophan (Trp) 6.2 12.2 0, 41 35.1
Valine (Val) 3.5 8. 7 0, 31 24.4
* The relative frequency of the marker being included in the model across 1000 bootstrap resamples.
Supplemental Table 3. Metabolite-enzyme links as identified in the DKD molecular model and 






Produces nitric oxide (NOS) which is a messenger molecule 
with diverse functions throughout the body. In macrophages, 
NO mediates tumoricidal and bactericidal actions. Also has 
nitrosylase activity and mediates cysteine S-nitrosylation of 
cytoplasmic target proteins such COX2.
ADMA is an endogeous inhibitor of eNOS (NOS3) function.
Aspargine 
Glutamine
ASNS Asparagine Synthase: Adenosine triphosphate + L-Aspartic 
acid + L-Glutamine + Water → Adenosine monophosphate + 
Pyrophosphate + L-Asparagine + L-Glutamic acid
Asparagine SLC1A1 Solute carries family member 1, L-Asp cotransporter





L-Arginine + NADPH + Oxygen → Citrulline + Nitric oxide + 
NADP + Water 
NADPH + N-(o)-Hydroxyarginine + Oxygen + Hydrogen Ion → 
NADP + Nitric oxide + Citrulline + Water 
L-Arginine + Oxygen + NADPH + Hydrogen Ion → Nitric oxide + 
Citrulline + NADP + Water
lysoPC a C16:0
lysoPC a C16:1 
PC aa C36:0 
PC aa C42:2
PLA2G1B PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl 
groups in 3-sn-phosphoglycerides.




Tryptophan IDO1 Catalyzes the cleavage of the pyrrol ring of tryptophan and 
incorporates both atoms of a molecule of oxygen.
Supplemental Table 4. GFR change after response period in the validation cohort (n=50)
≤30% decrease in UAE >30% decrease in UAE
GFR change after response period 
(mL/min/1.73m2/year)
-5.2 (3.2) -3.2 (3.7)
Data are reported as mean ± standard deviation (SD).
CHAPTER 6
The beneficial impact of atrasentan on 
a urinary metabolite panel previously 
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ABSTRACT
Objectives: A specific panel of 13 urinary organic acid metabolites reflecting mitochondrial 
function was previously identified to be reduced in patients with diabetic kidney disease. 
We aimed to assess correlations between these 13 urinary metabolites and eGFR, and 
the effect of atrasentan therapy on these metabolites in the previously conducted RADAR 
study.
Methods: RADAR was a placebo controlled double blind trial in patients with type 2 
diabetes and nephropathy (n=150) randomly allocated to 12 weeks treatment with 
placebo or atrasentan 0.75-1.25 mg/d, as adjunct to renin-angiotensin-system inhibition. 
Urinary metabolomics was performed with gas-chromatography mass spectrometry. A 
combined average index of the metabolites was developed, producing a single-valued 
index called the Metabolomics Signature of Diabetic Kidney Disease (MSDKD) panel.
Results: Concentrations of four out of 13 metabolites were below detectable levels. Of the 
remaining nine metabolites, six were reduced in patients with eGFR <60 compared to ≥60 
ml/min/1.73m2, and eight showed significant correlation with baseline eGFR (all p≤0.015, 
with Bonferroni correction). In patients with eGFR <60 ml/min/1.73m2, the MSDKD panel 
changed by -0.31 (95%CI -0.60 to -0.02; p=0.035), -0.08 ( -12 to 0.29; p=0.43) and 0.01 
(-0.21 to 0.19; p=0.913) in placebo, atrasentan 0.75 mg/d and 1.25 mg/d, respectively 
after 12 weeks. The MSDKD panel difference compared to placebo was 0.13 (-0.17 to 
0.43; p=0.40) and 0.35 (0.05 to 0.65; p=0.024) for atrasentan 0.75 mg/d and 1.25 mg/d, 
respectively. Change in eGFR correlated with changes in all nine metabolites and the 
MSDKD panel (R2= 0.42; p<0.001) in the atrasentan groups.
Conclusions: Urinary metabolites reflecting mitochondrial function correlated with 
eGFR in patients with type 2 diabetes and nephropathy. Treatment with atrasentan 
1.25 mg/d for 12 weeks stabilized the levels of the metabolites while they declined with 
placebo treatment.
INTRODUCTION
Metabolomics, the measurement of small molecules in a biological sample, is an 
emerging science that holds promise for identifying novel biomarkers of kidney disease. 
The metabolome integrates the biological information of the genome, transcriptome, 
proteome, and overall enzymatic reactions of an individual, therefore enabling the 
detection of short and long-term physiological or pathological changes occurring in 
diseases. The systematic analyses of metabolites in urine of patients with kidney disease 
may help characterize the biochemical pathways of kidney disease progression. A recent 
urinary metabolomics study identified a novel metabolomics signature of diabetic kidney 
disease [1]. This signature, consisting of 13 metabolites, was found to be significantly 
and consistently reduced in patients with diabetic kidney disease compared to healthy 
controls. These metabolites are regulated by mitochondrial function, suggesting a 
reduced mitochondrial content and function in diabetic kidney disease [1].
Significant efforts are being invested in improving risk assessment of renal function decline 
using novel biomarker panels to improve on the available clinical parameters [2]. Of equal 
importance is to determine whether that risk of renal function decline is modifiable with 
drug therapy. The endothelin system is a promising target for intervention in diabetic 
kidney disease [3]. Blockade of the endothelin A receptor with selective inhibitors such as 
atrasentan have shown clinical meaningful reductions in albuminuria [4, 5], which predicts 
long-term renoprotection. Urinary metabolomics may aid in discovering novel biomarkers 
for monitoring of a potential long-term renoprotective drug efficacy. 
The first aim of this study was to assess the correlation between the previously 
discovered metabolomics signature of diabetic kidney disease and estimated glomerular 
filtration rate (eGFR) in patients with type 2 diabetes and nephropathy participating in 
the Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With 
AtRasentan (RADAR) trial, and the second aim was to evaluate the effect of atrasentan on 
these urinary metabolites.
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METHODS
Patients and study design
For the present study, data and urine samples from 150 participants from the RADAR 
study (NCT01356849) were used. The detailed design, rationale, and study outcome for 
this study has been previously published [4]. In brief, the RADAR study assessed the 
effect of the endothelin A receptor antagonist atrasentan on albuminuria. Patients at least 
18 years of age with type 2 diabetes, and nephropathy were eligible for participation in the 
clinical trial. Estimated glomerular filtration rate (eGFR) was calculated with the CKD-EPI 
formula and ranged between 30 and 75 ml/min/1.73m2 [6]. All participants had a urinary 
albumin to creatinine ratio (UACR) between 300 and 3500 mg/g, received the maximum 
tolerated labeled daily dose of a renin-angiotensin-aldosterone-system inhibitor, and 
90% of patients were receiving a diuretic. Main exclusion criteria were a history of 
moderate or severe edema, pulmonary edema, pulmonary hypertension, or heart failure. 
Patients were randomly allocated to 12 weeks treatment with atrasentan 0.75 mg/d, 1.25 
mg/d, or matched placebo. The study protocol was approved by an Independent Ethics 
Committee and local and central review boards. All participants signed written informed 
consent before the start of any study-specific procedure.
Measurements and outcomes
Study visits were scheduled at week 1, 2, and every 2 weeks thereafter. Physical 
examination including measurement of blood pressure, body weight, and assessment 
of edema were performed at every visit. Three consecutive first morning void urine 
collections were collected at each visit, with the exception of week 1, for determination of 
urinary albumin and creatinine concentrations. Urine samples were collected and stored 
at -80°C until further processing. Albuminuria was determined by the geometric mean of 
three first morning voids.
Metabolomics measurements
Urine samples were analyzed with a quantitative gas chromatography-mass spectrometry 
platform to measure the following organic acid metabolites: 3-OH-isobutyrate, citric acid, 
homovanillic acid, 2-ET-3-OH-propionate, glycolic acid, 3-OH-propionate, aconitic acid, 
uracil, 3-OH-isovalerate, 3-methyl adipic acid, tiglylglycine, 3-methyl-crotonyl glycine, 
and 2-methyl acetoacetate. Urine samples were pre-processed as previously described 
[1] and subsequently applied by injection onto a 30 m 3 0.32 mm column (Agilent DB-5) 
in a gas chromatogram (Agilent 5890) and eluted with a 4°C/min gradient of 70–300°C; 
analytes were detected by electron impact mass spectrometry (Agilent 5973 mass 
selective detector). Each compound was identified by spectrum and confirmed ratio of 
a qualifying ion and quantifying ion. The quantifying ion’s integrated current was used to 
estimate concentration based on standard curves for targeted metabolites or based on a 
ratio to 4-nitrophenol or the oximated derivative of 2-ketocaproic acid. The results were 
expressed as µmol organic acid per mmol urinary creatinine. 
A combined average index of the metabolites was developed to produce a single-valued 
index, henceforth referred to as the Metabolomics Signature of Diabetic Kidney Disease 
(MSDKD) panel. To compute the MSDKD panel per sample, the concentration of each 
of the metabolites was first normalized by subtracting its mean over the whole data set 
(i.e., for all time points and treatment groups), then dividing that value by its standard 
deviation (also over the whole data set), and then taking the average of the normalized 
metabolite concentrations. This methodology has been used previously to combine 
multiple biomarkers into an index panel [7, 8].
Statistical analyses
Analyses were performed using SAS version 9.3. Baseline characteristics with normal 
distribution were reported as mean and standard deviation (SD), characteristics 
with skewed distribution were reported as median and inter quartile range [IQR], and 
categorical variables were reported as number and percentage. UACR and metabolite 
concentrations were log transformed for analyses to account for their skewed distribution. 
P-values were two-tailed and values <0.05 with Bonferroni correction for multiple testing 
were considered statistically significant.
The correlations between the metabolites and eGFR at baseline were computed with 
Pearson’s correlation. In addition, metabolite concentrations at baseline were compared 
by independent samples t-test between groups stratified by baseline eGFR <60 ml/
min/1.73m2 (n=121) or ≥ 60 ml/min/1.73m2 (n=29). In order to assess the effect of atrasentan 
on the metabolites from baseline to week 6 and week 12, the difference between the 
log transformed metabolite concentrations was calculated in the atrasentan treatment 
group and the placebo group and assessed with the Welch t-test. Simple binomial 
probabilities of the differences being positive were tested under the null hypothesis of 
no treatment effect, assuming no correlation between the metabolites. A mixed-effects 
model repeated-measures analysis for change in the metabolites from baseline to week 
6 and week 12 was performed to ascertain whether there were differences the MSDKD 
panel between the placebo group and the atrasentan treatment group over follow-up. 
The model included treatment, visit, treatment-by-visit interaction as factors. Visits 
were included as repeated measure units from the same patients. To allow generality 
for the covariance structure for the repeated measures, the variance-covariance matrix 
was assumed to be unstructured, i.e., purely data dependent. The correlations between 
changes in metabolites with changes in eGFR were tested by linear regression in a 
combined treatment group.
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RESULTS
Correlation between metabolites and eGFR
At baseline, nine of the 13 urinary metabolites from the metabolomics signature of 
diabetic kidney disease were detectable in urine. Levels of the other four metabolites were 
below detection in the majority of patients and therefore excluded from further analysis. 
Lower concentrations of the nine measurable metabolites were significantly associated 
with lower baseline eGFR for eight metabolites (all p≤0.015 after Bonferroni correction 
for multiple testing; Table 1). Concentrations of six of the metabolites were significantly 
higher in patients with a baseline eGFR ≥60 ml/min/1.73m2 compared to patients with a 
baseline eGFR <60 ml/min/1.73m2 (p<0.05 after Bonferroni correction for multiple testing; 
Table 1). A MSDKD index was calculated based on the average values of the 9 and 
found to be significantly associated with the eGFR at baseline (R2=0.43, p<0.0001) and 
markedly different in patients with eGFR <60 vs. >60 ml/min/1.73m2 (Table 1).


















Aconitic acid 0.38 <0.001 13.9 [10.9, 18.5] 20.0 [15.7, 24.8]  0.008
Citric acid 0.33 <0.001 141.6 [77.7, 217.2] 216.1 [102.5, .46.5]  0.135
Glycolic acid 0.35 <0.001 14.4 [11.9, 16.9] 18.2 [16.3, 22.1]  0.004
Homovanillic acid 0.06  0.440 0.9 [0.7, 1.2] 1.0 [0.7, 1.2]  0.999
2-ET-3-OH-
Propionate
0.27 <0.001 0.3 [0, 0.7] 0.7 [0.2, 1.0]  0.027
3-OH-Isobutyrate 0.26  0.001 17.7 [13.1, 22.6] 24.7 [18.5, 34.5]  0.015
3-OH-Isovalerate 0.40 <0.001 5.2 [4.3, 6.9] 7.8 [6.6, 10.1] <0.001
3-OH-Propionate 0.40 <0.001 0.8 [0.6, 1.1] 1.6 [1.2, 2.0] <0.001
Uracil 0.20  0.015 2.1 [1.2, 2.8] 3.1 [2.6, 4.1]  0.163
MSDKD panel 0.43 <0.001 -0.07 [-0.5, 0.3] 0.6 [0.04, 0.9] <0.001
Concentrations are reported as median [25th quartile, 75th quartile]. The 4 non-detectable 
metabolites from the metabolomics signature of mitochondrial dysfunction: 3-Methyl adipic acid, 
Tiglylglycine, 3-methyl-crotonyl glycine, 2-Methyl acetoacetate. 
Effect of atrasentan on the metabolites in patients with eGFR <60 ml/min/1.73m2
Because this panel of metabolites was significantly reduced in patients with a baseline 
eGFR <60 ml/min/1.73m2, we assessed whether atrasentan treatment would alter 
the metabolite concentrations in this subgroup. The baseline demographics, clinical 
biochemical characteristics as well as the baseline metabolite levels were well balanced 
between the placebo and treatment groups (Supplemental Table 1). The concentrations 
of the metabolites decreased during the 12 weeks follow up period in the placebo group. 
In contrast, the same metabolites remained stable in the atrasentan groups over the 12 
weeks follow-up period. Accordingly, relative to placebo, eight of the nine metabolites 
increased in the atrasentan 0.75 mg/d group and all nine individual metabolites increased 
in the atrasentan 1.25 mg/d group at week 12 (p=0.0019 for increase in all nine metabolites 
versus placebo assuming no correlation between the metabolites; Figure 1). 
In patients with eGFR <60 ml/min/1.73m2 at baseline, the MSDKD panel changed by 
-0.31 (95%CI -0.60 to -0.02; p=0.035) at week 12 in the placebo group (Figure 2). In the 
atrasentan 0.75 mg/d group, the MSDKD panel changed by -0.08 (95% CI -0.12 to 0.29; 
p=0.43) and it changed by 0.01 (95%CI -0.21 to 0.19; p=0.913) in the atrasentan 1.25 
mg/d group. This resulted in a dose dependent difference in the MSDKD panel compared 
to placebo of 0.13 (95% CI -0.17 to 0.43; p=0.40) and 0.35 (95% CI 0.05 to 0.65; p=0.024) 
for the atrasentan 0.75 mg/d and 1.25 mg/d groups, respectively at week 12 (Figure 2). 
The effect of atrasentan on the metabolites was not different when the overall population 
was analyzed (Supplemental Figure 1).
Correlations between change in eGFR and changes in metabolites
In the placebo group, there were no significant associations observed between change 
in eGFR and change in the metabolites. In contrast, changes in eGFR significantly and 
positively correlated with changes in all nine metabolites (Table 2) in the combined 
atrasentan treatment group. A change in the MSDKD panel was also significantly 
associated with change in eGFR (R2= 0.42; p<0.001; Table 2 and Supplemental Figure 2). 
The individual metabolites and the MSDKD panel did not correlate with baseline UACR 
(Supplemental Table 2) or changes in UACR at week 12 (Supplemental Table 3).
139138
Effect of atrasentan therapy on metabolitesChapter 6
6
Figure 1. Effects of atrasentan A) 0.75mg/d and B) 1.25 mg/d relative to placebo on individual 
metabolites at week 6 and week 12 in patients with baseline eGFR <60 mL/min/m2 (n=121). Figure 2. Mean values of the MSDKD panel and 95% confidence intervals for placebo, atrasentan 
0.75 mg/d, and atrasentan 1.25 mg/d in patients with baseline eGFR <60 mL/min/m2 (n=121). 
* P-value 0.024 for comparison placebo vs. atrasentan 1.25 mg/d.
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Table 2. Correlations between change in eGFR and change in metabolites between baseline and 
12 weeks of follow-up in patients with baseline eGFR <60 mL/min/m2 (n=121).
Change in eGFR
β S.E. R2 P-value
Placebo (n=24)
  ΔAconitic acid 4.9 5.8 0.03 0.407
  ΔCitric acid -0.2 4.4 0.00 0.964
  ΔGlycolic acid -1.8 6.4 0.00 0.778
  ΔHomovanillic acid 7.3 7.7 0.04 0.358
  Δ2-ET-3-OH-Propionate 11.9 7.6 0.11 0.135
  Δ3-OH-Isobutyrate 1.0 4.4 0.00 0.815
  Δ3-OH-Isovalerate 2.6 7.0 0.01 0.712
  Δ2-3-OH-Propionate 3.7 6.5 0.02 0.577
  ΔUracil 0.2 4.7 0.00 0.963
  ΔMSDKD panel 0.7 1.3 0.02 0.573
Atrasentan (n=97)
  ΔAconitic acid 21.3 5. 5 0.16 <.001
  ΔCitric acid 14.1 3.2 0.20 <.001
  ΔGlycolic acid 30.8 5.6 0.27 <.001
  ΔHomovanillic acid 25.1 9.4 0.08 0.009
  Δ2-ET-3-OH-Propionate 22.1 5.6 0.17 <.001
  Δ3-OH-Isobutyrate 18.7 4.0 0.22 <.001
  Δ3-OH-Isovalerate 37.1 5.8 0.34 <.001
  Δ2-3-OH-Propionate 23.9 4.6 0.25 <.001
  ΔUracil 7.2 3.5 0.05 0.043
  ΔMSDKD panel 8.6 1.1 0.42 <.001
 
DISCUSSION
This study demonstrated that concentrations of urinary metabolites from a metabolomics 
signature of diabetic kidney disease were significantly correlated with eGFR levels in 
patients with type 2 diabetes and nephropathy. The levels of the metabolites remained 
stable after 12 weeks of treatment with atrasentan 1.25 mg/d whereas they decreased 
with placebo. Individual changes in the metabolites after 12 weeks of treatment positively 
correlated with changes in eGFR. Since lower metabolite concentrations reflect reduced 
mitochondrial content and renal function [1], it is plausible that treatment with atrasentan 
may stabilize mitochondrial function. 
The correlation between lower urinary metabolite concentrations and lower eGFR were 
consistent with the findings of the prior discovery study of the metabolomics signature 
of diabetic kidney disease in patients with diabetic nephropathy [1]. That study reported 
that urinary concentrations of 12 of the 13 metabolites were significantly decreased 
in patients with diabetic nephropathy compared to patients with type 2 diabetes and 
eGFR>60 ml/min/1.73m2. Systems biology analysis revealed that the reduced metabolite 
concentrations were associated with generalized reduction in mitochondrial function, a 
hypothesis confirmed by kidney biopsy staining samples from healthy volunteers and 
patients with diabetic nephropathy [4]. In this present study, four metabolites could not be 
detected. Since levels of the urine metabolites were found to be lower with reduced eGFR 
[1], it may be possible that eGFR was too low to detect these metabolites. In the current 
study we also investigated changes in metabolites over time during placebo or treatment 
with the endothelin A receptor antagonist atrasentan. We focused our investigation on 
patients with baseline eGFR <60 ml/min/1.73m2 as metabolites were reduced in these 
patients. Interestingly, atrasentan increased the individual metabolite levels relative 
to placebo, suggesting that atrasentan may preserve aspects of renal mitochondrial 
function. In the combined MSDKD panel, a significant difference between placebo and 
1.25mg/d atrasentan was observed, but not between placebo and 0.75 mg/d atrasentan, 
indicating a dose-dependent effect on these metabolites. On one hand, it may be possible 
that atrasentan directly stabilizes mitochondrial function. On the other hand, endothelin 
receptor antagonists have been shown to decrease mitotic activity and have anti-
inflammatory effects, which may affect mitochondrial function [3, 9]. In association with 
data from patients and animal models, an improvement in renal mitochondrial function 
could be expected to improve underlying renal structure and function [1, 10]. 
What is known about the interaction between the endothelin system and mitochondrial 
function? Recent studies suggest that endothelin regulates mitochondrial biogenesis by 
inhibiting the transcriptional regulator peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α) [11, 12]. Inhibition of endothelin by atrasentan could stimulate 
PGC-1α and increase mitochondrial biogenesis. Additionally, results from animal studies 
suggest that endothelin receptor blockade attenuates cardiac injury and impairment of 
mitochondrial biogenesis, and decreased endothelin-1 induced by endothelin-converting 
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enzyme-1 inhibition directly leads to cardioprotection and preserved mitochondrial 
biogenesis [11]. Increased mitochondria content could result in increased or stabilized 
mitochondrial-derived metabolites. An overall stabilization in mitochondrial function may 
provide a new hypothesis for a beneficial renoprotective effect of atrasentan in human 
diabetic kidney disease as several of the reduced mitochondrial-derived metabolites are 
closely correlated with eGFR [1]. The individual metabolites and the MSDKD panel did not 
correlate with changes in UACR. This implies that the treatment effect on the metabolites 
is unrelated to the effect on albuminuria. Although of importance, these results should be 
interpreted with caution since the 12 weeks follow-up is too short to adequately assess 
drug effects on overall renal function. A long-term trial is currently ongoing (SONAR trial 
NCT01858532) that will assess the potential long-term renoprotective effect of atrasentan 
and will allow further study of atrasentan’s potential renoprotective mechanism of action.
To the best of our knowledge, the present study appears to be a first in examining 
metabolite profiles in response to therapy in type 2 diabetes and nephropathy. While 
an increasing number of studies are exploring the metabolomics profiles in relation to 
renal function decline in type 2 diabetes [13, 14], studies evaluating the effects of drug 
treatment on metabolomics profiles are lacking. Such studies are needed to identify 
novel biomarkers for monitoring drug efficacy as well as providing insights into molecular 
mechanisms of drug effects and drug response variability.
Limitations of this study include a short follow-up duration and thus inability to assess 
whether the change in metabolites are sustained after the 12 weeks follow-up period. 
Another limitation is the lack of plasma samples that would allow for an assessment of 
whether the metabolites regulated in urine were similarly regulated in plasma. This would 
help to assess whether the effect of the drug therapy was potentially systemic or primarily 
renal, and whether these urinary changes reflect systemic changes, renal changes only, 
or simply changes in renal hemodynamics or creatinine handling. Moreover, urinary 
metabolites could be filtered in the glomerulus and the glomerular barrier function can 
be improved by endothelin receptor antagonists, thereby potentially altering the urinary 
metabolite concentration [4, 15]. This study, however, is unable to address these potential 
confounders. Further analysis of samples from this study and future studies will be of great 
interest to further understand the role of targeted metabolomics in identifying potentially 
important biomarkers and possible surrogates for diabetic kidney disease progression. 
Finally, the relatively small number of participants limited the study power and strength of 
the conclusions. Validation of this urinary metabolomics panel in larger studies with hard 
clinical endpoints is required to support our hypothesis. Additional studies may provide 
the data for using metabolites as a potential companion diagnostic or as a surrogate 
marker for atrasentan treatment in type 2 diabetes complications. 
In conclusion, a specific panel of urinary metabolites linked to mitochondrial function was 
significantly correlated with eGFR levels in patients with type 2 diabetes and nephropathy. 
Treatment with atrasentan 1.25 mg/d for 12 weeks stabilized the levels of the metabolites 
while they declined with placebo treatment, implying that treatment with atrasentan may 
prevent their reduction as compared to placebo. Long-term hard outcome trials are 
required to confirm these findings and assess whether the short-term changes in these 
metabolites portend an improvement in long-term renal function.
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Supplemental Table 2. Pearson’s correlations between metabolites and UACR at baseline in the 
overall RADAR population (n=150).
Individual Metabolites Pearson’s Coefficient P-value
Aconitic acid -0.17 0.039
Citric acid -0.05 0.583
Glycolic acid 0.05 0.565






MSDKD panel -0.0359 0.663
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Supplemental Table 3. Correlations between change in UACR and change in metabolites between 
baseline and 12 weeks of follow-up in patients with baseline eGFR <60 mL/min/m2 (n=121).
Change in UACR
β S.E. R2 P-value
Placebo (n=24)
  ΔAconitic acid 0.07 0.40 0.002 0.855
  ΔCitric acid 0.57 0.27 0.18 0.050
  ΔGlycolic acid 0.16 0.44 0.01 0.726
  ΔHomovanillic acid -0.19 0.54 0.01 0.725
  Δ2-ET-3-OH-Propionate 0.13 0.55 0.003 0.811
  Δ3-OH-Isobutyrate 0.23 0.30 0.03 0.447
  Δ3-OH-Isovalerate 0.12 0.48 0.003 0.810
  Δ2-3-OH-Propionate 0.35 0.44 0.03 0.432
  ΔUracil 0.12 0.32 0.01 0.700
  ΔMSDKD panel 0.05 0.09 0.01 0.594
Atrasentan (n=97)
  ΔAconitic acid 0.59 0.43 0.02 0.174
  ΔCitric acid 0.83 0.24 0.13 <.001
  ΔGlycolic acid 0.68 0.47 0.03 0.156
  ΔHomovanillic acid 0.49 0.71 0.01 0.492
  Δ2-ET-3-OH-Propionate 0.63 0.43 0.03 0.149
  Δ3-OH-Isobutyrate 0.30 0.32 0.01 0.357
  Δ3-OH-Isovalerate 0.57 0.51 0.02 0.268
  Δ2-3-OH-Propionate 0.59 0.39 0.01 0.459
  ΔUracil 0.12 0.26 0.003 0.633
  ΔMSDKD panel 0.20 0.11 0.04 0.060
Supplemental Figure 1. Mean values of the MSDKD panel and 95% confidence intervals in the 
overall RADAR population (n=150) randomly assigned to placebo, atrasentan 0.75 mg/d, or 
atrasentan 1.25 mg/d.
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Supplemental Figure 2. Correlation of change in the MSDKD panel with change in eGFR from 
baseline to week 12 in the atrasentan group in patients with baseline eGFR <60 mL/min/m2 (n=97). 
The dotted horizontal grey line indicates the mean eGFR change during 12 weeks of atrasentan 
treatment, and the vertical dotted line indicates the mean change in the MSDKD panel. The dark grey 
diagonal line is the regression line.
CHAPTER 7
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SUMMARY
The overall premise of this thesis is that earlier detection of diabetic kidney disease (DKD) 
in patients with type 2 diabetes and subsequent intervention for increased risk of DKD 
may ultimately help alleviate the burden of end-stage renal disease (ESRD). One strategy 
to accomplish this may be the use of novel biomarker panels to predict progression 
of renal disease. Furthermore, this thesis examined the use novel biomarker panels for 
predicting response to therapy and monitoring the effect of therapeutic intervention.
Type 2 diabetes is a multifactorial disease involving different pathophysiologic molecular 
processes with a heterogeneous histopathological structure [1]. We hypothesized that a 
combination of biomarkers that capture different pathogenic processes of renal damage 
may provide a more realistic picture of a patient’s actual pathophysiological status. This 
thesis therefore focused on multiple biomarkers in a panel instead of single biomarkers. 
Recent advances in laboratory and throughput technologies have helped generate an 
expansive inventory of potential biomarker panels for renal disease in type 2 diabetes [2].
Novel biomarker panels can be used not only for risk prediction at early disease stages 
but also importantly for drug response prediction and monitoring therapeutic effect. Many 
patients with type 2 diabetes treated with guideline recommended therapy still face a high 
risk of renal disease progression and variability in response to therapy. Therefore, the 
use of novel biomarker panels in the context of drug response prediction or monitoring 
therapy is extremely important to reduce variability drug response, minimize side 
effects, or off-target effects, which is observed with many established and novel drugs. 
Using novel biomarkers to improve on current practices to improve risk stratification, 
help increase our understanding of renal disease pathophysiology, and provide insight 
into novel therapeutic targets can ultimately help reduce the burden renal disease in 
type 2 diabetes.
Novel biomarker panels as predictors of renal disease
In Part 1, this thesis investigated the predictive ability of novel biomarker panels for 
the progression of renal disease in patients with type 2 diabetes. Novel biomarkers 
may provide deeper understanding into the pathophysiology of DKD. Furthermore, 
identification of progression-associated molecular pathways via biomarkers as proxy 
may also help to identify novel therapeutic targets. Given the complexity of the multiple 
pathophysiological processes involved in progression of renal disease in type 2 diabetes 
together with the intra-individual variability of biomarkers, it is questionable if a single 
biomarker may possess useful diagnostic and prognostic power. Alternatively, a panel 
of clearly defined biomarkers may provide a more robust and reproducible tool as it 
tolerates changes in single biomarkers without jeopardizing their diagnostic ability. A 
combination of biomarkers that capture different pathways of renal damage may provide 
a more realistic picture of a patient’s actual pathophysiological status and hence may 
yield better assessment of disease prognosis performance. 
Chapter 2 presented an observational cohort study of 82 patients with type 2 diabetes 
followed for 4 years. A panel of 13 novel biomarkers was associated with accelerated 
renal function decline beyond established risk markers. This study identified a novel panel 
of biomarkers representing different pathways of renal damage, including inflammation, 
fibrosis, angiogenesis, and endothelial function. This combined panel improved prediction 
of accelerated renal function decline in patients with type 2 diabetes on top of established 
risk markers. There was however, no external validation of this biomarker panel, and the 
small sample size limit the study results. Therefore, these results need to be validated in a 
large, prospective cohort to validate and assess this novel biomarker panel’s applicability 
in a broad type 2 diabetes population. 
The measurement of peptides and metabolites, known as proteomics and metabolomics, 
have emerged as strong tools in biomarker discovery [3]. Chapter 3 assessed the 
predictive ability of plasma proteomics classifiers to improve risk prediction of transition 
in albuminuria stage in patients with hypertension or type 2 diabetes. The developed 
plasma proteomics classifiers were able to predict transition in stage of albuminuria in 
hypertensive patients and transition from micro- to macroalbuminuria in patients suffering 
from type 2 diabetes. This was independent of established the renal risk markers urinary 
albumin excretion (UAE) and estimated glomerular filtration rate (eGFR), as well as use 
of renin-angiotensin-aldosterone system (RAAS) intervention. The plasma peptides 
identified in hypertension and type 2 diabetes were linked to pathways associated with 
established mechanisms of renal disease, including fibrosis, inflammation, angiogenesis, 
and mineral metabolism. These results support the growing evidence of using peptidomic 
platforms as a strategy for risk stratification of renal disease.
Metabolomics is another potential tool to discover novel biomarkers for renal disease. 
Chapter 4 investigated the predictive ability of urine and plasma metabolites for the 
development of diabetic nephropathy in patients with type 2 diabetes. In this discovery 
study, plasma metabolites histidine and butenolycarnatine and urine metabolites hexoses, 
glutamine, and tyrosine were able to predict progression from micro- to macroalbuminuria 
on top of established renal risk markers in type 2 diabetes. These metabolites did not 
predict albuminuria progression in patients with hypertension, suggesting a type 2 
diabetes specific metabolite profile. In this study, the urinary metabolome profile performed 
better than the plasma profile, and addition of the plasma metabolites to the urinary 
metabolites did not improve outcome prediction. This may point at urinary metabolomics 
as a better clinical approach to identify people with type 2 diabetes at risk of progressive 
renal disease (also due to practical advantages of collecting urine compared to blood 
samples). However, the results from the plasma metabolomics may be useful to identify 
underlying mechanisms and pathways of disease and should not be neglected. Again, 
external validation of these metabolites is still needed to give firm conclusions for these 
metabolites’ predictive ability in a broader population.
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Novel biomarker panels for predicting response to therapy
First choice, guideline recommended therapy for treatment of hypertension and 
albuminuria for patients with type 2 diabetes are either angiotensin converting enzyme 
inhibitors (ACEi) or angiotensin II receptor blockers (ARB) [4]. However, many patients 
still do not respond optimally to ACEi or ARBs [5-9]. This may result in progressive 
renal function loss. One approach to reduce this variation in response to therapy is 
to use novel biomarkers to predict response to therapy. Chapter 5 discovered and 
externally validated a serum metabolite classifier that significantly improves prediction 
of albuminuria response to ARBs in patients with diabetes mellitus on top of traditional 
clinical risk markers. Metabolites included in the classifier were related to oxidative 
stress, inflammation, and fibrosis pathways. Specifically, increased nitric oxide synthase 
3 (NOS3) activity appears to be a factor in predicting the albuminuria lowering response to 
ARBs. These findings suggest the use of serum metabolomics as a tool to help optimize 
treatment of antiproteinuric ARB intervention. Metabolites included in the classifier were 
assigned to stress/inflammation pathways and downstream consequences of fibrosis 
and extra cellular matrix remodeling. Furthermore, NOS3 appears to be a specific factor 
relevant in ARB response. These results indicate that for assessing drug response, both 
disease progression status and specific drug molecular effects need to be taken into 
account. The results of this metabolomics study support the growing evidence of using 
omics tools as a strategy to improve treatment of renal disease in diabetes mellitus. The 
complementary use of omics platforms can help bring personalized medicine one step 
closer to implementation in clinical practice.
Novel biomarker panels for monitoring the effect of therapy
Novel biomarker panels can be used to monitor the response to treatment. Chapter 6 
investigated the effect of atrasentan on the previously identified metabolomics signature 
of diabetic kidney disease [10]. This study first demonstrated that concentrations of 
urinary metabolites from this panel were significantly correlated with eGFR levels in 
patients with type 2 diabetes and nephropathy. We then assessed the beneficial impact 
of atrasentan on this urinary metabolite panel. Treatment with atrasentan 1.25 mg/d for 12 
weeks stabilized the levels of the metabolites while they declined with placebo treatment, 
implying that treatment with atrasentan may prevent their reduction as compared 
to placebo. Individual changes in the metabolites after 12 week treatment positively 
correlated with changes in eGFR. Lower metabolite concentrations have been previously 
shown to reflect reduced mitochondrial content and renal function [10], therefore, it is 
plausible that treatment with atrasentan may stabilize several aspects of mitochondrial 
function. Long-term hard outcome trials are required to assess whether these short-term 
beneficial effects portend in improvement in overall renal function. Results of further 
studies may help provide insight into the mechanisms through which atrasentan exerts 
renoprotective effects and may yield novel biomarkers to monitor response to therapy in 
patients with type 2 diabetes and DKD.
FUTURE PERSPECTIVES
Before a biomarker or panel of biomarkers can be used in clinical practice, it needs to 
be extensively validated in large studies to assess accuracy, reproducibility, sensitivity, 
and specificity. The translation of a biomarker or a combination of biomarkers from 
discovery to clinical practice is a process full of pitfalls and limitations. In 2009, Hlatky 
et al. proposed a framework for the development of biomarkers in collaboration with the 
American Heart Association [11], as listed in Box 1. Unfortunately, many novel biomarker 
panel studies for renal disease in type 2 diabetes stop at the end of the third phase 
[12], and do not proceed to external validation or assessment of clinical utility. More 
awareness and investments need to be made to preform studies in the clinical utility 
and clinical outcome phases in order to start implementing novel biomarker panels in 
clinical practice. Better study designs that can test the biomarkers’ practical value to 
translate the predictive power of a biomarker panel into decisions for clinical practice 
would help address non-acceptance of novel biomarkers by professional communities. 
Furthermore, collaborations between academia and industry may be a strategy to share 
expertise from different areas, to promote effective dissemination of results, and to 
support implementation of these findings in clinical practice.
Box 1. Framework for the development of novel biomarkers. 
Adapted from Hlatky et al. Circulation 2009 [11]
1. Proof of concept
Do novel marker levels differ between subjects with and without outcome?
2. Prospective validation
Does the novel marker predict development of future outcomes in a prospective cohort 
or nested case-cohort/case-cohort study?
3. Incremental value
Does the novel marker add predictive information to established, standard risk markers?
4. Clinical utility
Does the novel risk marker change predicted risk sufficiently to change recommended 
therapy?
5. Clinical outcomes
Does use of the novel risk marker improve clinical outcomes, especially when tested in a 
randomized clinical trial?
6. Cost-effectiveness
Does use of the marker improve clinical outcomes sufficiently to justify the additional 
costs of testing and treatment?
Much of this thesis consists of research performed with the SysKid program (Systems 
Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment, www.syskid.eu). 
SysKid was a large-scale European research project involving both academia and industry 
partners. SysKid aimed at improving characterization of the molecular mechanisms 
underlying diabetic kidney disease at the interference of the molecular impact of individual 
drugs in order to tailor optimal therapy to individual patients. Results and continuing 
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work stemming from SysKid have deepened our understanding of chronic kidney disease 
(CKD) in term of prevention, new diagnostic strategies, and treatment options for renal 
disease in diabetes and hypertension. Furthermore, there is an ongoing validation study 
in a large, type 2 diabetes population that will assess the validity of the novel biomarker 
panels described in Chapter 2-4 of this thesis. Though this validation study will not be 
able to provide further knowledge toward clinical utility or cost-effectiveness, there is the 
opportunity to evaluate the predictive ability of these novel biomarkers panels for hard 
renal outcomes. Furthermore, this validation study provides the opportunity to compare 
the biomarkers at early stage, mid stage, and late stage DKD.
Use of biomarker panels for risk stratification in clinical practice is one strategy to guide 
treatment decisions and target interventions for patients at highest risk for progressive 
renal disease. Within SysKid, validation of a novel urinary peptide panel known as the 
CKD273 score was performed [13]. This CE-MS based urinary proteomics classifier 
was developed in a cross-sectional study in CKD patient groups with varying underlying 
etiologies of disease [14]. The clinical utility of the CKD273 score is currently being tested in 
the Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention 
Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria 
(PRIORITY) trial (Clinical Trials Identifier NCT02040441) [15]. The PRIORITY trial will 
assess the clinical utility of the CKD273 score for the purpose of guiding treatment of 
patients with type 2 diabetes at high risk for renal disease progression. The PRIORITY 
trial uses the CKD273 score to identify patients at high risk of renal disease while still in 
early disease stages. The primary objective of the PRIORITY trial is to confirm whether 
urinary proteomics can predict development of microalbuminuria. The PRIORITY study 
will also assess whether high-risk patients identified with the CKD273 score will benefit 
from spironolactone therapy.
Current treatment of type 2 diabetes relies on optimal glycemic, lipid, and blood 
pressure control. Past randomized control studies has shown that targeting HbA1c, lipid 
management, and blood pressure control delays the progression of DKD [16-20]. However, 
even in these successful studies, the residual renal risk is still quite high, implying that the 
current treatment regime is insufficient to prevent progression to ESRD in a substantial 
proportion of patients. Given the large heterogeneity in pathophysiology of DKD and the 
substantial variability in response to renoprotective drugs, treatment strategies need 
to go in a new direction. Using novel biomarker panels to identify patients who would 
respond well to treatment before therapy has even been started, may help decrease 
variability in treatment response. An ideal scenario to implement use of novel biomarkers 
in clinical practice would be to identify individuals at risk for progressive disease while 
at the same time identify those who would respond well to treatment. However there 
is currently a paucity of studies that evaluate whether novel biomarkers predict drug 
response. Chapter 5 of this thesis is just the start in utilizing novel biomarkers to predict 
response to therapy, and future studies are needed to push this field forward.
Studies that assess whether treatment induced changes in novel biomarkers are 
associated with renal risk are lacking. This will be an area of interest for the future as it may 
help us to identify novel biomarkers that can be used to monitor drug efficacy, generate 
information about the molecular mechanisms through which drugs exert their effects, and 
provide insight into novel drug targets. It may be possible that a patient benefits from a 
drug without changing the urinary albumin levels and thus other biomarkers are needed to 
monitor drug efficacy or safety. Chapter 6 of this thesis provides some evidence towards 
proof of concept for use of a novel biomarker panel to monitor the effect of drug therapy, 
though long-term hard outcome trials are still required to confirm these findings and 
assess whether the short-term changes in these metabolites portend an improvement in 
long-term renal function.
In order to go beyond the status quo, novel approaches to treat patients with renal 
disease are necessary to improve disease outcomes. As advancing laboratory techniques 
become more and more realistic in clinical practice, the use of omics techniques as a tool 
to reduce the burden of renal disease complications represents a real strategy to improve 
disease diagnosis, prognosis, and treatment. Rich omics datasets have improved 
molecular phenotyping and characterization of the underlying molecular mechanisms 
of DKD on the level of individual patients. These datasets should also be used in the 
future to assess mechanisms of drug response and discover biomarkers that predict 
drug response. Collectively the omics methodologies, molecular process mapping, and 
from there developing novel biomarkers would contribute to the identification of the 
optimal therapeutic approach to provide the greatest benefit with minimal side effects 
or off-target effects (Figure 1). This may help improve on the current “trial-and-error” 
approach to choosing drugs for treatment of DKD in patients with type 2 diabetes and 
bring personalized medicine one step closer to clinical practice.
Figure 1. Creating a systems medicine approach to study drug response variability by adding post-
genomic information to the genotype information, thereby connecting the complex genotype with 
the phenotype.
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De veronderstelling die ten grondslag ligt aan dit proefschrift is dat vroegere opsporing 
van en interventie bij patiënten met diabetes mellitus type 2 die een verhoogd risico 
lopen op diabetische nefropathie uiteindelijk de ziektelast van eindstadium nierfalen 
(ESRD) kunnen verlichten. Een manier om dit doel te bereiken is het gebruik van nieuwe 
biomarkerpanels om progressie van nefropathie te voorspellen. Daarnaast werd in dit 
proefschrift de voorspellende waarde van nieuwe biomarkerpanels voor respons op 
therapie onderzocht. Tevens werd het monitoren van het effect van therapeutische 
interventie onderzocht. 
Diabetes mellitus type 2 is een multifactoriële ziekte waarin verschillende 
pathofysiologische moleculaire processen met heterogene histopathologische structuren 
betrokken zijn [1]. Wij veronderstelden dat een combinatie van biomarkers, die de 
verschillende pathologische processen van nierschade reflecteren, mogelijk een meer 
realistische weerspiegeling zijn van de actuele pathofysiologische status van een 
patiënt. Dit proefschrift richtte zich daarom op panels van meerdere biomarkers in plaats 
van individuele biomarkers. Recente ontwikkelingen in laboratorium- en throughput-
technieken hebben bijgedragen aan een uitgebreide lijst potentiële biomarkerpanels voor 
nefropathie in diabetes mellitus type 2 [2]. 
Nieuwe biomarkers kunnen naast risicovoorspelling in vroege ziektestadia ook gebruikt 
worden om respons op medicatie te voorspellen en om therapeutische effecten te 
monitoren. Veel patiënten met diabetes mellitus type 2, die volgens de richtlijnen worden 
behandeld, houden een hoog risico op progressie van nefropathie en vertonen en 
variabele respons op therapie. Het gebruik van nieuwe biomarkerpanels om het effect op 
therapie te voorspellen en te monitoren is van groot belang om de variatie in respons te 
verminderen, de kans op bijwerkingen te minimaliseren en de kans op off-targeteffecten 
te verkleinen die frequent optreden bij het gebruik van klassieke en nieuwe medicatie. 
Het gebruik van nieuwe biomarkers om de huidige klinische praktijk en risico-stratificatie 
te verbeteren draagt bij aan een beter begrip van de pathofysiologische processen van 
nefropathie, geeft inzicht in nieuwe farmaceutische aangrijpingspunten en kan uiteindelijk 
de ziektelast van diabetische nefropathie doen afnemen. 
Biomarkers als voorspellers van nefropathie
In deel 1 van dit proefschrift werd de voorspellende waarde van nieuwe biomarkerpanels 
voor progressie van nefropathie bij patiënten met diabetes mellitus type 2 onderzocht. 
Nieuwe biomarkers kunnen een beter inzicht geven in de pathofysiologie van diabetische 
nefropathie. Daarnaast kan identificatie van biomarkers als proxy voor moleculaire 
processen die geassocieerd zijn met progressie bijdragen aan de identificatie van 
nieuwe therapeutische aangrijpingspunten. Gezien de complexiteit van het grote aantal 
pathofysiologische processen die betrokken zijn bij de progressie van diabetes mellitus 
type 2 naast de intra-individuele variabiliteit van de biomarkers is het maar de vraag of 
een enkele biomarker voldoende diagnostische en voorspellende waarde kan hebben. 
Daarentegen kan een panel van duidelijk gedefinieerde biomarkers een robuuster en meer 
reproduceerbaar alternatief vormen, omdat het panel variatie in individuele biomarkers 
kan tolereren zonder de diagnostische kracht in gevaar te brengen. Een combinatie van 
biomarkers, die verschillende processen van nierschade weerspiegelen, kan een meer 
realistisch beeld geven van de actuele pathofysiologische status van een patiënt en 
daarmee een betere prognostische inschatting geven. 
Hoofdstuk 2 toonde een observationele cohortstudie van 82 patiënten met diabetes 
mellitus type 2 die gedurende vier jaar werden gevolgd. Een panel van dertien nieuwe 
biomarkers was geassocieerd met versnelde achteruitgang van de nierfunctie, bovenop 
traditionele risicomarkers. Deze studie identificeerde een nieuw panel biomarkers 
die verschillende processen van nierschade representeren, waaronder inflammatie, 
fibrosering, angiogenese en endotheelfunctie. Dit gecombineerde panel had een betere 
voorspellende waarde van versneld nierfunctieverlies in patiënten met diabetes mellitus 
type 2 bovenop traditionele risicomarkers. Er vond echter geen externe validatie van dit 
biomarkerpanel plaats en de kleine studiegroep beperkt de resultaten van deze studie. 
De resultaten moeten daarom in een groot, prospectief cohort gevalideerd worden om de 
toepasbaarheid van dit nieuwe panel biomarkers in een brede populatie patiënten met 
diabetes mellitus type 2 vast te stellen. 
Het meten van peptiden en metabolieten, ook bekend als proteomics en metabolomics, 
zijn sterke methoden gebleken om biomarkers te ontdekken [3]. Hoofdstuk 3 onderzocht 
de voorspellende waarde van plasma proteomics classifier om de risico-inschatting 
te verbeteren op verandering in albuminurie-stadium bij patiënten met hypertensie of 
diabetes mellitus type 2. De ontwikkelde plasma proteomics classifiers waren in staat 
om verandering in albuminurie-stadium te voorspellen in patiënten met hypertensie, 
daarnaast waren zij in staat de overgang van micro- naar macroalbuminurie te voorspellen 
in patiënten met diabetes mellitus type 2. Deze resultaten zijn onafhankelijk van zowel 
traditionele risicomarkers voor albuminurie en eGFR, als het gebruik van RAAS-medicatie. 
De plasma-peptiden die in hypertensie en diabetes mellitus type 2 werden geïdentificeerd, 
zijn gerelateerd aan processen die betrokken zijn bij bekende nefropathofysiologische 
processen, waaronder fibrosering, inflammatie, angiogenese en mineraalhuishouding. 
Deze resultaten ondersteunen het groeiende bewijs om peptidoomplatforms te gebruiken 
voor risicostratificatie in nefropathie. 
Metabolomics is een andere potentiële methode om nieuwe biomarkers voor nefropathie 
the ontdekken. Hoofdstuk 4 onderzocht de voorspellende waarde van urine- en 
plasmametabolieten voor het ontwikkelen van diabetische nefropathie in patiënten met 
diabetes mellitus type 2. In deze exploratieve studie bleken de plasmametabolieten 
histidine en butenoylcarnatine en de urinemetabolieten hoxoses, glutamine en tyrosine 
in staat om progressie van micro- naar macroalbuminurie te voorspellen bovenop 
traditionele risicomarkers in diabetes mellitus type 2. Deze metabolieten voorspelden 
geen albuminurieprogressie in patiënten met hypertensie, hetgeen een specifiek 
metabolietenprofiel suggereert voor diabetes mellitus type 2. In deze studie had het urine-
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metabolietenprofiel betere testeigenschappen dan het plasmaprofiel, ook verbeterde 
het toevoegen van de plasmametabolieten aan de urinemetabolieten de voorspellende 
eigenschappen niet. Dit zou erop kunnen wijzen dat urine metabolomics een betere 
klinische benadering is om patiënten met diabetes mellitus type 2 die risico lopen op 
progressieve nefropathie te identificeren (mede vanwege de praktische voordelen 
van het verzamelen van urine vergeleken met het verkrijgen van een bloedmonster). 
Desalniettemin zouden de uitkomsten van de plasmametabolieten behulpzaam kunnen 
zijn in het identificeren van onderliggende ziektemechanismen en –processen, zij zouden 
daarom niet veronachtzaamd moeten worden. Wederom is externe validatie van deze 
metabolieten nodig om stevige conclusies te kunnen trekken aangaande de voorspellende 
waarde van deze metabolieten in een bredere populatie. 
Nieuwe biomarkers als voorspeller voor respons op therapie
De therapie van eerste keuze volgens huidige richtlijnen voor de behandeling van 
hypertensie en albuminurie bij patiënten met diabetes mellitus type 2 bestaat uit 
angiotensine-converterend-enzym-remmers (ACEi) of angiotensine II-receptor 
blokkerende middelen (ARB) [4]. Veel patiënten reageren echter suboptimaal op ACEi of 
ARB [5-9]. Dit kan leiden tot progressief nierfunctieverlies. Een methode om deze variatie 
in therapierespons te verminderen is het gebruik van nieuwe biomarkers om de respons 
op therapie te voorspellen. In hoofdstuk 5 werd een serum metabolomics classifier 
ontdekt die de albuminurierespons op ARB significant beter voorspelde in patiënten 
met diabetes mellitus type 2 dan traditionele risicofactoren. Deze classifier werd in een 
extern cohort gevalideerd. De metabolieten die in deze classifier werden geïncludeerd, 
waren gerelateerd aan oxidatieve stress, inflammatie en fibrosering. Met name NOS3 
activiteit lijkt een voorspellende factor te zijn voor afname van albuminurie als respons op 
ARB. Deze bevindingen ondersteunen het gebruik van serum metabolomics als middel 
om de antiproteïnurische behandeling met ARB te optimaliseren. Metabolieten die in de 
classifier werden geïncludeerd worden toegeschreven aan processen die betrokken zijn 
bij stress/inflammatie en aan de downstream-effecten van fibrosering en remodellering 
van extracellulaire matrix. Daarnaast lijkt NOS3 een specifieke factor te zijn die relevant 
is voor de respons op ARB. Deze resultaten duiden erop, dat zowel ziekteprogressie 
als specifieke medicatie-afhankelijke moleculaire effecten meegewogen moeten worden 
om respons op medicatie in te schatten. De resultaten van deze metabolomics-studie 
ondersteunen het groeiende bewijs voor het gebruik van -omics als een strategie om 
de behandeling van nefropathie in diabetes mellitus te verbeteren. Het complementaire 
gebruik van –omics-platforms kan geïndividualiseerde behandeling een stap dichterbij de 
klinische praktijk brengen. 
Nieuwe biomarkers om behandeleffecten te monitoren
Nieuwe biomarkerpanels kunnen gebruikt worden om het effect van behandeling te 
monitoren. Hoofdstuk 6 onderzocht het effect van atrasentan op een eerder vastgesteld 
metabolietenprofiel van diabetische nefropathie [10]. Deze studie toonde eerst aan 
dat de concentratie van urinemetabolieten uit dit panel significant geassocieerd waren 
met de eGFR van patiënten met diabetes mellitus type 2 en nefropathie. Daarna werd 
onderzocht of atrasentan een gunstig effect had op dit urine-metabolietenprofiel. De 
metabolieten bleven stabiel na 12 weken behandeling met atrasentan, terwijl deze 
afnamen bij gebruik van placebo. Verandering in individuele metabolieten na 12 weken 
behandeling waren positief gecorreleerd met verandering in eGFR. Aangezien lagere 
concentraties van metabolieten een verminderde mitochondriële inhoud en nierfunctie 
weerspiegelen [10], is het aannemelijk dat behandeling met atrasentan verschillende 
aspecten van de mitochondriële functie stabiliseert. Harde uitkomsten op lange termijn 
zijn nodig om vast te stellen of deze gunstige korte-termijn effecten een verbetering van 
de nierfunctie voorspellen. De resultaten van vervolgonderzoeken kunnen inzicht geven in 
de nefroprotectieve werkingsmechanismen van atrasentan en zouden nieuwe biomarkers 
op kunnen leveren om de respons op therapie in patiënten met diabetes mellitus type 2 
en diabetische nefropathie te bewaken. 
TOEKOMSTPERSPECTIEF
Voordat een biomarker of een panel van biomarkers in de klinische praktijk gebruikt 
kan worden, moeten deze uitgebreid gevalideerd worden in grote studies, om precisie, 
reproduceerbaarheid, sensitiviteit en specificiteit vast te stellen. De vertaling van een 
biomarker of combinatie van biomarkers van ontdekking tot klinische praktijk is een 
weg vol valkuilen en beperkingen. In 2009 hebben Hlatky et al. in samenwerking met de 
American Heart Association [11] randvoorwaarden voorgesteld voor de ontwikkeling van 
biomarkers, zoals is weergegeven in Box 1. Helaas stoppen veel studies naar nieuwe 
biomarkerpanels voor nefropathie bij diabetes mellitus type 2 aan het einde van de derde 
fase [12] en worden de panels niet in een extern cohort gevalideerd, noch wordt het klinisch 
nut vastgesteld. Er moet meer bewustwording komen voor en investering in studies in 
de fase van klinische uitkomsten, zodat nieuwe biomarkerpanels in de klinische praktijk 
geïmplementeerd kunnen worden. Een betere studieopzet, die de praktische waarden 
van biomarkers kan testen, en die de voorspellende waarde van de biomarkerpanel kan 
vertalen naar klinische beslissingen, kan bijdragen aan de achterblijvende acceptatie 
van nieuwe biomarkerpanels door zorgprofessionals. Verder zou samenwerking tussen 
universitaire en farmaceutische onderzoeksgroepen een manier kunnen zijn om expertise 
in verschillende deelgebieden met elkaar te kunnen delen, om zo effectieve verspreiding 
van onderzoeksresultaten te bevorderen en de implementatie van de bevindingen in de 
klinische praktijk te ondersteunen. 
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Box 1. Randvoorwaarden voor de ontwikkeling van nieuwe biomarkers. Naar Hlatky et al. 
Circulation 2009 [11]
1. Proof of concept
verschillen de concentraties van nieuwe biomarkers tussen studiedeelnemers met en 
zonder de uitkomstmaat? 
2. Prospectieve validatie
voorspellen de nieuwe biomarkers de ontwikkeling van de uitkomstmaat in een 
prospectief cohort, of in een geneste case-cohort/case-cohort studie? 
3. Toegevoegde waarde
voegt de nieuwe biomarker voorspellende waarde toe aan gevestigde, standaard 
risicomarkers? 
4. Klinisch nut
verandert de nieuwe biomarker het voorspelde risico voldoende om het therapeutisch 
beleid aan te passen? 
5. Klinische uitkomsten
verbetert het gebruik van de nieuwe biomarker klinische uitkomsten, met name in een 
gerandomiseerde klinische trial? 
6. Kosteneffectiviteit 
verbetert het gebruik van de nieuwe biomarker de klinische uitkomsten voldoende om de 
extra kosten van testen en behandelingen te rechtvaardigen? 
 
Een groot deel van dit proefschrift bestaat uit onderzoek dat uitgevoerd is binnen het 
SysKid-programma (Systems Biology toward Novel Chronic Kidney Disease Diagnosis and 
Treatment, www.syskid.eu). SysKid was een grootschalig Europees onderzoeksproject 
waarin zowel universiteiten als de farmaceutische industrie deelnamen. SysKid beoogde 
de onderliggende moleculaire mechanismen van diabetische nefropathie op het 
kruispunt met de moleculaire impact van individuele medicijnen beter te karakteriseren 
om zodoende individuele behandeling van patiënten te optimaliseren. Resultaten van 
eerder en huidig onderzoek van SysKid hebben ons begrip van chronische nierziekte 
vergroot, met name in het kader van preventie, nieuwe diagnostische strategieën en 
behandelopties voor diabetische en hypertensieve nefropathie. Momenteel vindt er een 
validatiestudie plaats in een groot cohort patiënten met diabetes mellitus type 2, waarin 
de validiteit getest wordt van de nieuwe biomarkerpanels die in de hoofdstukken 2-4 van 
dit proefschrift beschreven zijn. Hoewel deze validatiestudie geen nieuwe kennis in de zin 
van klinische toepasbaarheid of kosteneffectiviteit zal voortbrengen, geeft deze studie 
wel de mogelijkheid om de voorspellende waarde van deze nieuwe biomarkerpanels 
voor harde nefrologische uitkomsten vast te stellen. Verder geeft deze validatiestudie de 
mogelijkheid om de biomarkers in vroege, intermediaire en late stadia van diabetische 
nefropathie te vergelijken. 
Het gebruik van biomarkerpanels voor risicostratificatie in de klinische praktijk is een 
manier om behandelbeslissingen te sturen en interventies toe te spitsen op patiënten 
met het hoogste risico op progressieve nierziekte. Binnen SysKid werd een nieuw 
biomarkerpanel, bekend als CKD273, gevalideerd [13]. Deze urine proteomics classifier, 
gebaseerd op CE-MS, was ontwikkeld in een cross-sectionele studie in patiëntengroepen 
met chronische nierziekte met verschillende onderliggende etiologie [14]. Het klinische nut 
van de CKD273 score wordt momenteel onderzocht in de Proteomic Prediction and Renin 
Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In 
TYpe 2 Diabetic Patients With Normoalbuminuria (PRIORITY) trial (Clinical Trials Identifier 
NCT02040441) [15]. De PRIORITY-trial zal het klinische nut van de CKD273 score 
onderzoeken in het sturen van de behandeling van patiënten met diabetes mellitus type 2 
met een hoog risico op progressieve nefropathie. De PRIORITY-trial gebruikt de CKD273-
score om patiënten met een hoog risico op nefropathie te identificeren terwijl zij nog in de 
vroege fase van de ziekte verkeren. Het primaire doel van de PRIORITY-trial is om vast 
te stellen of urine proteomics de ontwikkeling van microalbuminurie kan voorspellen. De 
PRIORITY-trial zal ook onderzoeken of hoog-risico-patiënten baat hebben bij behandeling 
met spironolacton. 
De huidige behandeling van diabetes mellitus type 2 is gestoeld op optimale regulatie van 
serum glucose, lipiden en bloeddruk. In het verleden hebben gerandomiseerde studies 
aangetoond dat adequate controle van HbA1c, lipiden en bloeddruk het ontstaan en de 
progressie van diabetische nefropathie vertragen [16-20]. De absolute reductie van het 
risico op nefropathie is echter laag, en dit impliceert dat het huidige behandelregime 
in een substantieel aantal patiënten onvoldoende is om progressie tot eindstadium-
nierfalen te voorkomen. Gezien de grote heterogeniteit in pathofysiologie van diabetische 
nefropathie en de grote variabiliteit in de respons op nefroprotectieve medicatie is het 
noodzakelijk een nieuwe richting te zoeken voor de behandelstrategieën. Het gebruik 
van nieuwe biomarkerpanels om patiënten te identificeren die een gunstige respons 
op therapie zullen vertonen voordat de therapie wordt begonnen, kan de variabiliteit 
in behandelrespons verminderen. In een ideaal scenario voor de implementatie van 
nieuwe biomarkers in de klinische praktijk worden patiënten geïdentificeerd die zowel 
een hoog risico lopen op ziekteprogressie, als waarschijnlijk een gunstige respons op 
behandeling zullen vertonen. Er is momenteel echter gebrek aan studies die onderzoeken 
of nieuwe biomarkers de respons op therapie kunnen voorspellen. In Hoofdstuk 5 van dit 
proefschrift wordt slechts een begin gemaakt met het gebruik van nieuwe biomarkers 
om behandelrespons te voorspellen. Nader onderzoek is nodig om die veld verder te 
ontwikkelen. 
Er zijn geen studies waarin onderzocht werd of medicatie-geïnduceerde verandering 
in nieuwe biomarkers geassocieerd is met risico op nierschade. Dit is een interessant 
onderzoeksgebied voor de toekomst, aangezien op deze manier nieuwe biomarkers 
geïdentificeerd kunnen worden die ons in staat stellen om effectiviteit van medicatie te 
monitoren, en er meer informatie beschikbaar komt over de moleculaire mechanismen 
waardoor de medicatie hun effect bewerkstelligen en nieuwe medicamenteuze 
aangrijpingspunten ontdekt kunnen worden. Wellicht heeft een patiënt baat bij een 
medicament, terwijl er geen verandering optreedt in albuminurie. Daarom zijn andere 
biomarkers nodig om effectiviteit en veiligheid van medicijnen te monitoren. Hoofdstuk 6 
van dit proefschrift voorziet in proof of concept voor het gebruik van nieuwe biomarkers 
om effectiviteit van medicatie te monitoren, hoewel onderzoek naar harde lange-termijn-
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eindpunten nodig zijn om de bevindingen van ons onderzoek te ondersteunen en vast te 
stellen of de korte-termijnveranderingen in de metabolieten een verbetering in nierfunctie 
op lange termijn voorspellen. 
Nieuwe behandelmethoden zijn nodig om ons een stap verder te brengen in het 
verbeteren van ziekte-uitkomsten. Nu geavanceerde laboratoriumtechnieken gerealiseerd 
worden in de klinische praktijk wordt het gebruik van -omics technieken als manier om 
de ziektelast van de complicaties van nierziekten te verminderen een reële strategie 
om diagnostiek, prognose en behandeling van nefropathie te verbeteren. In een ideaal 
scenario om het gebruik van nieuwe biomarkers in de klinische praktijk te implementeren 
worden patiënten geïdentificeerd die zowel een hoog risico lopen op ziekteprogressie, 
als een gunstige respons op behandeling laten zien. Grote –omics-datasets hebben de 
moleculaire fenotypering en karakterisering van de onderliggende moleculaire processen 
van diabetische nefropathie in individuele patiënten verbeterd. Deze datasets zouden ook 
in de toekomst gebruikt moeten worden om mechanismen van medicatierespons vast te 
stellen en om nieuwe biomarkers te ontdekken die de respons op medicatie voorspellen. 
De –omics-methodologie zou samen met het in kaart brengen van moleculaire processen 
en vandaaruit het ontwikkelen van nieuwe biomarkers bij kunnen dragen aan het 
identificeren van de optimale therapeutische benadering om de maximale therapeutische 
winst te verenigen met minimale bijwerkingen en off-targeteffecten (Figuur 1). Deze 
benadering zou de huidige manier van trial-and-error in de keuze voor medicatie voor 
patiënten met diabetes mellitus type 2 kunnen verbeteren en zou geïndividualiseerde 
therapie een stap dichter bij de klinische praktijk kunnen brengen. 
Figuur 1. De ontwikkeling van een systems medicine approach om de variatie in respons op medicatie 
te onderzoeken, door het toevoegen van post-genomic informatie aan het genotype, waardoor het 
complexe genotype verbonden wordt aan het fenotype. 
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